<SEC-DOCUMENT>0001021771-23-000057.txt : 20230713
<SEC-HEADER>0001021771-23-000057.hdr.sgml : 20230713
<ACCEPTANCE-DATETIME>20230712184708
ACCESSION NUMBER:		0001021771-23-000057
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20230711
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230713
DATE AS OF CHANGE:		20230712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioRestorative Therapies, Inc.
		CENTRAL INDEX KEY:			0001505497
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				911835664
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37603
		FILM NUMBER:		231085481

	BUSINESS ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747
		BUSINESS PHONE:		(631) 760-8100

	MAIL ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stem Cell Assurance, Inc.
		DATE OF NAME CHANGE:	20101110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8kdtd07112023.htm
<DESCRIPTION>FORM 8-K DATED JULY 11, 2023
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:brtx="http://biorestorative.com/20230711" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Certilman Balin Adler & Hyman, LLP
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_57ceb1ef023543318985e8bd0e45e890" contextRef="c20230711to20230711" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_7373dd1aa23f4895bcc44a2d4b5a7646" contextRef="c20230711to20230711">0001505497</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="brtx-20230711.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20230711to20230711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-11</xbrli:startDate><xbrli:endDate>2023-07-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <div style="font-family: 'Times New Roman', Times, serif;">
      <div style="color: #000000;">
        <div>
          <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

        <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

        <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

        <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

        <div style="padding-bottom: 6pt;"> <br />
        </div>

        <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_c84329cecbed42efb8c9ec7782a0dc7f" contextRef="c20230711to20230711">8-K</ix:nonNumeric></div>

        <div style="text-align: center; font-weight: bold; font-size: 12pt;"> <br />
        </div>

        <div style="text-align: center; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

        <div style="text-align: center; font-size: 10pt;">PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>

        <div style="font-size: 10pt;"> <br />
        </div>

        <div style="text-align: center; font-size: 10pt; font-weight: bold;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_51a9baca9f4646ce91064466f3412b3a" contextRef="c20230711to20230711" format="ixt:date-monthname-day-year-en">July 11, 2023</ix:nonNumeric></div>

        <div style="font-size: 12pt;"> <br />
        </div>

        <div style="text-align: center; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_0f5eaf8704c542c9bc0c5ee2fe6d3136" contextRef="c20230711to20230711">BioRestorative Therapies, Inc.</ix:nonNumeric><br />
        </div>

        <div style="font-size: 10pt; text-align: center;">(Exact name of registrant as specified in its charter) </div>

        <div style="font-size: 10pt; padding-bottom: 12pt;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">


  <tr>

    <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid #000000; font-size: 10pt;">
                <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_8ae875c516fd4621ac0308557708d402" contextRef="c20230711to20230711" format="ixt-sec:stateprovnameen">Nevada</ix:nonNumeric><br />
                </div>
              </td>

    <td style="width: 5%; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;">
                <div style="text-align: left; ">&#160;</div>
              </td>

    <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid #000000; font-size: 10pt;">
                <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_68d36ba51bee4918a7ffb96c8ba84153" contextRef="c20230711to20230711">001-37603</ix:nonNumeric><br />
                </div>
              </td>

    <td style="width: 5%; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;">
                <div style="text-align: left; ">&#160;</div>
              </td>

    <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid #000000; font-size: 10pt;">
                <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_6ddffba6f23b4162af2814a714ffda92" contextRef="c20230711to20230711">30-1341024</ix:nonNumeric><br />
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 30%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: center; ">(State or other jurisdiction <br />
                  of incorporation)</div>
              </td>

    <td style="width: 5%; vertical-align: bottom; font-size: 10pt;">
                <div style="text-align: left; ">&#160;</div>
              </td>

    <td style="width: 30%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: center; ">(Commission <br />
                  File Number)</div>
              </td>

    <td style="width: 5%; vertical-align: bottom; font-size: 10pt;">
                <div style="text-align: left; ">&#160;</div>
              </td>

    <td style="width: 30%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: center; ">(IRS Employer <br />
                  Identification No.)</div>
              </td>

  </tr>


</table>
        <div style="font-size: 8pt;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">


  <tr>

    <td style="width: 47%; vertical-align: bottom; border-bottom: 2px solid #000000; text-align: center; font-size: 10pt; font-weight: bold;">
                <div><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_753b20eef43b436196eb0b8eab6deccd" contextRef="c20230711to20230711">40 Marcus Drive</ix:nonNumeric></div>
                <div><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_0311f9a9dc204ecfa1381e7c7399be94" contextRef="c20230711to20230711">Melville</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_c2fedba71bcc4544ba9725a27d45ef2d" contextRef="c20230711to20230711" format="ixt-sec:stateprovnameen">New York</ix:nonNumeric></div>
              </td>

    <td style="width: 6%; vertical-align: bottom; padding-bottom: 2px; font-size: 10pt;">
                <div style="text-align: left;">&#160;</div>
              </td>

    <td style="width: 47%; vertical-align: bottom; text-align: center; font-size: 10pt; border-bottom: 2px solid #000000; font-weight: bold">
                <div><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_484ea381ac4e43219dd9dc43322a84a0" contextRef="c20230711to20230711">11747</ix:nonNumeric><br />
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 47%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: center; ">(Address of principal executive offices)</div>
              </td>

    <td style="width: 6%; vertical-align: bottom; font-size: 10pt;">
                <div style="text-align: left; ">&#160;</div>
              </td>

    <td style="width: 47.48%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: center; ">(Zip code)</div>
              </td>

  </tr>


</table>
        <div style="font-size: 10pt;"> <br />
        </div>

        <div style="text-align: center; font-size: 10pt;">Registrant's telephone number, including area code (<ix:nonNumeric name="dei:CityAreaCode" id="Fact_2a075e71a9ae481281424db10e1288cd" contextRef="c20230711to20230711">631</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_1c15988241e94cf7bfd5e7779a12fb38" contextRef="c20230711to20230711">760-8100</ix:nonNumeric></div>

        <div style="font-size: 10pt;"> <br />
        </div>

        <div style="text-align: center; font-size: 10pt;">Not Applicable</div>

        <div style="text-align: center; font-size: 10pt;">(Former Name or Former Address, if Changed Since Last Report)</div>

        <div style="font-size: 10pt;"> <br />
        </div>

        <div style="text-align: center; font-size: 10pt;"><span style="text-decoration: underline;">Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:</span></div>

        <div style="text-align: center; font-size: 10pt;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="width: 100%; text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">


  <tr>

    <td style="width: 33.33%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: center; "><span style="text-decoration: underline;">Title of each class</span></div>
              </td>

    <td style="width: 33.33%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: center; "><span style="text-decoration: underline;">Trading Symbol(s)</span></div>
              </td>

    <td style="width: 33.33%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: center; "><span style="text-decoration: underline;">Name of each exchange on which registered</span></div>
              </td>

  </tr>

  <tr>

    <td style="width: 33.33%; vertical-align: bottom; font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_9082fe7351a74f7db86d6d7023a5433e" contextRef="c20230711to20230711">Common Stock, $0.0001 par value</ix:nonNumeric><br />
              </td>

    <td style="width: 33.33%; vertical-align: bottom; font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_865eb3856cab4952856a090937718d3b" contextRef="c20230711to20230711">BRTX</ix:nonNumeric><br />
              </td>

    <td style="width: 33.33%; vertical-align: bottom; font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_1497fd799cc24bacb5c9156a735b7680" contextRef="c20230711to20230711">NASDAQ</ix:nonNumeric> Capital Market<br />
              </td>

  </tr>


</table>
        <div style="margin-top: 6pt; margin-bottom: 6pt; font-size: 10pt;"><br />
        </div>

        <div style="text-align: left; margin-top: 6pt; margin-bottom: 6pt; font-size: 10pt;"> Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
          provisions (see General Instruction A.2. below): </div>

        <div style="text-align: left; margin-bottom: 7.1pt; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_68c17f4c53bf43c48804a0324f88ef67" contextRef="c20230711to20230711" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities
          Act (17 CFR 230.425)</div>

        <div style="text-align: left; margin-bottom: 6.95pt; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_2161e2eb022a42b8967438cf1a1ef348" contextRef="c20230711to20230711" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Soliciting material pursuant to Rule 14a-12 under the Exchange
          Act (17 CFR 240.14a-12)</div>

        <div style="text-align: left; margin-bottom: 6.95pt; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_250cb1127b4a4f62acf3c2b81dd53016" contextRef="c20230711to20230711" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 14d-2(b) under
          the Exchange Act (17 CFR 240.14d-2(b))</div>

        <div style="text-align: left; margin-bottom: 2.05pt; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_00629eb185c84c28be5d243f0d26f90b" contextRef="c20230711to20230711" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Pre-commencement communications pursuant to Rule 13e-4(c) under
          the Exchange Act (17 CFR 240.13e-4(c))</div>

        <div style="margin-bottom: 2.05pt; font-size: 10pt;"> <br />
        </div>

        <div style="text-align: left; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act
          of 1934 (&#167;240.12b-2 of this chapter):</div>

        <div><br />
        </div>

        <div style="text-align: left; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_217436b5f8a646589c8f7c3d310163d0" contextRef="c20230711to20230711" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

        <div><br />
        </div>

        <div style="text-align: left; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
          provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

        <div style="margin-top: 6pt;">
          <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /> </div>

      </div>

    </div>

    <div> <br />
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

    </div>

    <div>
      <div style="font-size: 10pt;">
        <div><br />
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 14.36%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item 1.01.</div>
            </td>

    <td style="width: 85.64%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Entry into a Material Definitive Agreement.</div>
            </td>

  </tr>


</table>
      <div style="font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">On July 11, 2023, BioRestorative Therapies, Inc. (the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;)
        with several institutional buyers and accredited investors (the &#8220;Purchasers&#8221;) pursuant to which the Company agreed to sell and issue to the Purchasers an aggregate of 685,033 shares of the Company&#8217;s common stock, par value $0.0001 per share (the
        &#8220;Shares&#8221;), in a registered direct offering (the &#8220;Offering&#8221;) at an offering price of $3.03 per share. The Offering is expected to close on or about July 13, 2023, subject to satisfaction of customary closing conditions.</div>

      <div style="font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The gross proceeds of the Offering will be approximately $2.1 million, before deducting placement agent fees and expenses and offering
        expenses payable by the Company. The Company intends to use the net proceeds from the Offering in connection with its clinical trials with respect to its lead cell therapy candidate, <span style="font-family: 'Times New Roman',Times,serif; font-style: italic;">BRTX-100</span>, pre-clinical research and development with respect to its metabolic <span style="font-family: 'Times New Roman',Times,serif; font-style: italic;">ThermoStem Program</span> and for general corporate purposes
        and working capital.</div>

      <div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The Shares are being offered pursuant to the Company&#8217;s effective registration statement on Form S-3 and accompanying base prospectus
        (File No. 333-269631), previously filed with and declared effective by the Securities and Exchange Commission.</div>

      <div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">In connection with the Offering, the Company entered into a placement agency agreement dated July 11, 2023 (the &#8220;Placement Agency
        Agreement&#8221;), with Titan Partners Group LLC, a division of American Capital Partners, LLC (the &#8220;Placement Agent&#8221;), pursuant to which the Company agreed to pay the Placement Agent a cash fee equal to 6.0% of the gross proceeds of the Offering and
        reimburse it up to $60,000 for out-of-pocket expenses for legal fees and other expenses.</div>

      <div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The Purchase Agreement contains customary representations, warranties and agreements by the Company, conditions to closing,
        indemnification obligations of the Company and the Purchasers, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of such
        agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties.</div>

      <div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> </span><span style="font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The foregoing descriptions of the Purchase Agreement and the Placement Agency Agreement are not complete and are qualified in their
        entirety by reference to the full texts of the Purchase Agreement and the Placement Agency Agreement, copies of which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.&#160; A
        copy of the legal opinion of Certilman Balin Adler &amp; Hyman, LLP relating to the legality of the issuance and sale of the Shares in the Offering is attached as Exhibit 5.1 to this Current Report on Form 8-K.</div>

      <div style="font-size: 10pt;"><br />
      </div>

      <div style="font-size: 10pt;">
        <div style="font-size: 10pt;">
          <div><br />
          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 14.36%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item 8.01.</div>
              </td>

    <td style="width: 85.64%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Other Events.</div>
              </td>

  </tr>


</table>
        <div><br /></div>

      </div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">On July 11, 2023, the Company issued a press release regarding the pricing of the Offering. A copy of the press release is attached to
        this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.</div>

      <div style="font-size: 10pt;">
        <div style="font-size: 10pt;">
          <div><br />
          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 14.36%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Item 9.01.</div>
              </td>

    <td style="width: 85.64%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Financial Statements and Exhibits.</div>
              </td>

  </tr>


</table>
        <div><br /></div>

      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td rowspan="1" style="width: 10%; vertical-align: top; font-size: 10pt;">(d)</td>

    <td rowspan="1" style="width: 80.8%; vertical-align: top; font-size: 10pt;"><span style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><span style="text-decoration: underline;">Exhibits</span></span></td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 10%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td rowspan="1" style="width: 80.8%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Number</div>
            </td>

    <td style="width: 80.8%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 80.8%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">5.1</div>
            </td>

    <td style="width: 80.8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Opinion of Certilman Balin Adler &amp; Hyman, LLP.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">10.1</div>
            </td>

    <td style="width: 80.8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Purchase Agreement, dated July 11, 2023, by and between the Company and the Purchasers.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">10.2</div>
            </td>

    <td style="width: 80.8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Placement Agency Agreement, dated July 11, 2023, by and between the Company and the Placement Agent.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">99.1</div>
            </td>

    <td style="width: 80.8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Press release of the Company, dated July 11, 2023.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">104</div>
            </td>

    <td style="width: 80.8%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Cover Page Interactive Data File (embedded within the Inline&#160; XBRL document).</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div>
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

        <div style="font-size: 10pt;"><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
          behalf by the undersigned hereunto duly authorized.</div>

        <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><br />
        </div>

        <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; border-collapse: separate; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">


  <tr>

    <td valign="top" style="width: 50%;">&#160;</td>

    <td valign="top" style="width: 38%;" colspan="2"><strong>BIORESTORATIVE THERAPIES, INC.</strong><br />
                </td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" style="width: 50%;">&#160;</td>

    <td valign="top" style="width: 3%;">&#160;</td>

    <td valign="top" style="width: 35%;">&#160;</td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" align="left" style="width: 50%; padding-bottom: 2px;">
                  <div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left;">Dated:&#160; July 11, 2023<br />
                  </div>
                </td>

    <td valign="top" style="width: 3%; padding-bottom: 2px;">
                  <div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: left;">By: </div>
                </td>

    <td valign="top" align="left" style="width: 35%; border-bottom: #000000 2px solid; white-space: nowrap;">/s/ Lance Alstodt<br />
                </td>

    <td valign="top" style="width: 12%; padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" style="width: 50%;">&#160;</td>

    <td valign="top" style="width: 3%;">&#160;</td>

    <td valign="bottom" align="left" style="width: 35%; white-space: nowrap;">Lance Alstodt<br />
                </td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" style="width: 50%;">&#160;</td>

    <td valign="top" style="width: 3%;">&#160;</td>

    <td valign="top" style="width: 35%;">Chief Executive Officer<br />
                </td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>

  <tr>

    <td valign="top" style="width: 50%;">&#160;</td>

    <td valign="top" style="width: 3%;">&#160;</td>

    <td valign="top" style="width: 35%;">&#160;</td>

    <td valign="top" style="width: 12%;">&#160;</td>

  </tr>


</table>
        </div>

        <div style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><br />
        </div>

      </div>

    </div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ex5_1.htm
<DESCRIPTION>OPINION OF CERTILMAN BALIN ADLER & HYMAN, LLP
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Certilman Balin Adler & Hyman, LLP
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>Exhibit 5.1<br>
  </div>
  <div> <br>
  </div>
  <div> <br>
  </div>
  <div> <br>
  </div>
  <div> <br>
  </div>
  <div> <img src="image00001.jpg"></div>
  <div> <br>
  </div>
  <div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"><font style="font-size: 8pt; font-family: 'Times New Roman',Times,serif;">F</font><font style="font-size: 8pt;">RED <font style="font-family: 'Times New Roman',Times,serif;">S. S</font>KOLNIK</font></div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 8pt;"><font style="font-size: 8pt; font-family: 'Times New Roman',Times,serif;">P</font><font style="font-size: 8pt;">ARTNER</font></div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 8pt;">D<font style="font-family: 'Times New Roman',Times,serif;">IRECT </font>D<font style="font-family: 'Times New Roman',Times,serif;">IAL </font>516.296.7048</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 8pt;">fskolnik@certilmanbalin.com</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 252pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">July 11, 2023</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">BioRestorative Therapies, Inc.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">40 Marcus Drive</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Suite One</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Melville, New York 11747</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Ladies and Gentlemen:</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">We have acted as counsel to BioRestorative Therapies, Inc., a Nevada corporation (the &#8220;Company&#8221;), in connection with the
      Registration Statement on Form&#160;S-3 (File No.&#160;333-269631) (the &#8220;Registration Statement&#8221;) filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) pursuant to the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the rules&#160;and
      regulations thereunder (the &#8220;Rules&#8221;), which became effective on February&#160;14, 2023. You have asked us to furnish our opinion as to the legality of the 685,033 shares of common stock of the Company, par value $0.0001 per share (the &#8220;Shares&#8221;), which are
      registered under the Registration Statement and which are to be issued and sold by the Company pursuant to the Securities Purchase Agreement, dated as of July 11, 2023, by and between the Company and the purchasers signatory thereto (the &#8220;Purchase
      Agreement&#8221;).</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">In connection with the furnishing of this opinion, we have examined originals, or copies certified or otherwise identified to
      our satisfaction, of the following documents:</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the Registration Statement;</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the prospectus supplement dated July 11, 2023 (the &#8220;Prospectus&#8221;); and</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the Purchase Agreement.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">In addition, we have examined (i)&#160;such corporate records of the Company as we have considered appropriate, including a copy of
      the amended and restated articles of incorporation and by-laws of the Company and copies of resolutions of the board of directors of the Company relating to the issuance of the Shares, and (ii)&#160;such other certificates, agreements and documents as we
      deemed relevant and necessary as a basis for the opinions expressed below. We have also relied upon the factual matters contained in the representations and warranties of the Company made in the documents reviewed by us and upon certificates of
      public officials and the officers of the Company.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">In our examination of the documents referred to above, we have assumed, without independent investigation, the genuineness of
      all signatures, the legal capacity of all individuals who have executed any of the documents reviewed by us, the authenticity of all documents submitted to us as originals, the conformity to the originals of all documents submitted to us as
      certified, photostatic, reproduced or conformed copies of valid existing agreements or other documents, the authenticity of all such latter documents and that the statements regarding matters of fact in the certificates, records, agreements,
      instruments and documents that we have examined are accurate and complete.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Based upon the above, and subject to the stated assumptions, exceptions and qualifications, we are of the opinion that the
      Shares have been duly authorized by all necessary corporate action on the part of the Company and, when issued, delivered and paid for as contemplated in the Registration Statement and in accordance with the terms of the Purchase Agreement, the
      Shares will be validly issued, fully paid and non-assessable.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The opinion expressed above is limited to the Nevada Revised Statutes. Our opinion is rendered only with respect to the laws,
      and the rules, regulations and orders under those laws, that are currently in effect.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">We hereby consent to the use of this opinion as an exhibit to the Company&#8217;s Current Report on Form&#160;8-K filed by the Company with
      the Commission on the date hereof, and to the use of our name under the heading &#8220;Legal Matters&#8221; contained in the base prospectus included in the Registration Statement and in the Prospectus Supplement. In giving this consent, we do not thereby admit
      that we come within the category of persons whose consent is required by the Securities Act or the Rules.</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 216.6pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Sincerely,</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; margin-left: 216.6pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">CERTILMAN BALIN ADLER &amp; HYMAN, LLP</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; margin-left: 216.7pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">By:</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 251.3pt;">&#160;</font></div>
    <div style="text-align: justify; margin-left: 216.7pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Fred Skolnik, a member of the Firm</div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ex10_1.htm
<DESCRIPTION>PURCHASE AGREEMENT BETWEEN COMPANY AND PLACEMENT AGENT
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Certilman Balin Adler & Hyman, LLP
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>Exhibit 10.1<br>
  </div>
  <div> <font style="font-size: 10pt;"><br>
    </font></div>
  <div><font style="font-size: 10pt;"> </font>
    <div style="text-align: center; text-indent: -36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">SECURITIES PURCHASE AGREEMENT</div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">This Securities Purchase Agreement (this &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Agreement</u></font>&#8221;) is dated as of [____], 2023, between BioRestorative Therapies, Inc., a Nevada corporation (the &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Company</u></font>&#8221;), and
      each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Purchaser</u></font>&#8221; and collectively the &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Purchasers</u></font>&#8221;).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective
      registration statement under the Securities Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully
      described in this Agreement.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good
      and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">ARTICLE I.</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font><font style="font-size: 10pt;">DEFINITIONS</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.1</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>&#160;Definitions</u></font>.&#160; In addition to the terms defined elsewhere in this
        Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1:</font></div>
    <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Acquiring Person</u></font>&#8221; shall
      have the meaning ascribed to such term in Section 4.4.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Action</u></font>&#8221;
      shall have the meaning ascribed to such term in Section 3.1(j).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Affiliate</u></font>&#8221;
      means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Board of
          Directors</u></font>&#8221; means the board of directors of the Company.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Business Day</u></font>&#8221;
      means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed; <font style="font-family: 'Times New Roman',Times,serif;"><u>provided</u></font>,
      <font style="font-family: 'Times New Roman',Times,serif;"><u>however</u></font>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;,
      &#8220;non-essential employee&#8221;&#160; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of
      commercial banks in The City of New York generally open for use by customers on such day.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Closing</u></font>&#8221;
      means the closing of the purchase and sale of the Shares pursuant to Section 2.1.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Closing Date</u></font>&#8221;
      means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasers&#8217; obligations to pay the Subscription Amount and (ii) the Company&#8217;s
      obligations to deliver the Shares, in each case, have been satisfied or waived, but in no event later than the second (2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup>) Trading Day following the date hereof.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Commission</u></font>&#8221;
      means the United States Securities and Exchange Commission.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Common Stock</u></font>&#8221;
      means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Common Stock
          Equivalents</u></font>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other
      instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Company Counsel</u></font>&#8221;
      means Certilman Balin Adler &amp; Hyman, LLP, with offices located at 90 Merrick Avenue, East Meadow, New York 11554.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Disclosure
          Schedules</u></font>&#8221; means the Disclosure Schedules of the Company delivered concurrently herewith.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Disclosure Time</u></font>&#8221;
      means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
      date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York
      City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>EGS</u></font>&#8221;
      means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Evaluation Date</u></font>&#8221;
      shall have the meaning ascribed to such term in Section 3.1(s).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Exchange Act</u></font>&#8221; means the
      Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>FCPA</u></font>&#8221;
      means the Foreign Corrupt Practices Act of 1977, as amended.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>FDA</u></font>&#8221;
      shall have the meaning ascribed to such term in Section 3.1(hh).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>FDCA</u></font>&#8221;
      shall have the meaning ascribed to such term in Section 3.1(hh).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>GAAP</u></font>&#8221;
      shall have the meaning ascribed to such term in Section 3.1(h).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Indebtedness</u></font>&#8221;
      shall have the meaning ascribed to such term in Section 3.1(aa).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Intellectual
          Property Rights</u></font>&#8221; shall have the meaning ascribed to such term in Section 3.1(p).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Liens</u></font>&#8221;
      means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Lock-Up
          Agreement</u></font>&#8221; means the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the directors and officers, in the form of <font style="font-family: 'Times New Roman',Times,serif;"><u>Exhibit A</u></font>
      attached hereto.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Material Adverse
          Effect</u></font>&#8221; shall have the meaning assigned to such term in Section 3.1(b).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Material Permits</u></font>&#8221;
      shall have the meaning ascribed to such term in Section 3.1(n).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Per Share
          Purchase Price</u></font>&#8221; equals $[_______, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Person</u></font>&#8221;
      means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Pharmaceutical
          Product</u></font>&#8221; shall have the meaning ascribed to such term in Section 3.1(hh).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Placement Agent</u></font>&#8221;
      means Titan Partners Group LLC, a division of American Capital Partners, LLC.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Proceeding</u></font>&#8221;
      means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Prospectus</u></font>&#8221;
      means the final prospectus filed for the Registration Statement.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Prospectus
          Supplement</u></font>&#8221; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the Commission and delivered by the Company to each Purchaser at the Closing.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Purchaser Party</u></font>&#8221;
      shall have the meaning ascribed to such term in Section 4.7.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Registration
          Statement</u></font>&#8221; means the effective registration statement with Commission file No. 333-269631 which registers the sale of the Shares to the Purchasers, and includes any Rule 462(b) Registration Statement.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Required
          Approvals</u></font>&#8221; shall have the meaning ascribed to such term in Section 3.1(e).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Rule 144</u></font>&#8221;
      means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and
      effect as such Rule.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Rule 424</u></font>&#8221;
      means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and
      effect as such Rule.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Rule 462(b)
          Registration Statement</u></font>&#8221; means any registration statement prepared by the Company registering additional Public Securities, which was filed with the Commission on or prior to the date hereof and became automatically effective pursuant
      to Rule 462(b) promulgated by the Commission pursuant to the Securities Act.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>SEC Reports</u></font>&#8221;
      shall have the meaning ascribed to such term in Section 3.1(h).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Securities Act</u></font>&#8221;
      means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Shares</u></font>&#8221;
      means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Short Sales</u></font>&#8221;
      means all &#8220;short sales&#8221; as defined in Rule 200 of Regulation SHO under the Exchange Act <font style="font-family: 'Times New Roman',Times,serif;">(but shall not be deemed to include </font>locating and/or borrowing<font style="font-family: 'Times New Roman',Times,serif;"> shares of Common Stock)</font>.&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Subscription
          Amount</u></font>&#8221; means, as to each Purchaser, the aggregate amount to be paid for Shares purchased hereunder as specified below such Purchaser&#8217;s name on the signature page of this Agreement and next to the heading &#8220;Subscription Amount,&#8221; in
      United States dollars and in immediately available funds.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Subsidiary</u></font>&#8221;
      means any subsidiary of the Company as set forth on <font style="font-family: 'Times New Roman',Times,serif;"><u>Schedule 3.1(a)</u></font>, and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
      or acquired after the date hereof.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Trading Day</u></font>&#8221;
      means a day on which the principal Trading Market is open for trading.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Trading Market</u></font>&#8221;
      means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York
      Stock Exchange,&#160; the Pink Open Market, OTCQB or the OTCQX (or any successors to any of the foregoing).</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Transaction
          Documents</u></font>&#8221; means this Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Transfer Agent</u></font>&#8221;
      means Transhare Corporation, the current transfer agent of the Company, with a mailing address of&#160; 17755 North US Highway 19, Suite 140, Clearwater, Florida 33764, and an email address of kwhiteside@transhare.com, and any successor transfer agent of
      the Company.</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Variable Rate
          Transaction</u></font>&#8221; shall have the meaning ascribed to such term in Section 4.10(b).</div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">ARTICLE II.</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font><font style="font-size: 10pt;">PURCHASE AND SALE</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">2.1</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Closing</u></font>.&#160; On the Closing Date, upon the
        terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $[_______ of Shares.&#160; Each Purchaser&#8217;s Subscription Amount as set forth on the
        signature page hereto executed by such Purchaser shall be made available for &#8220;Delivery Versus Payment&#8221; settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares, and the Company and each
        Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing.&#160; Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall take place remotely by electronic transfer of the
        Closing documentation.&#160; Unless otherwise directed by the Placement Agent, settlement of the Shares shall occur via &#8220;Delivery Versus Payment&#8221; (&#8220;DVP&#8221;)<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">&#160;</font>(i.e.,
        on the Closing Date, the Company shall issue the Shares registered in the Purchasers&#8217; names and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such
        Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company). Notwithstanding anything
        herein to the contrary, if at any time on or after the time of execution of this Agreement by the Company and an applicable Purchaser, through, and including the time immediately prior to the Closing (the &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Pre-Settlement Period</u></font>&#8221;), such Purchaser sells to any Person all, or any portion, of the Shares to be issued hereunder to such Purchaser at the Closing (collectively, the &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Pre-Settlement Shares</u></font>&#8221;), such Purchaser shall, automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed to be unconditionally bound to
        purchase, such Pre-Settlement Shares at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the Company&#8217;s receipt of the purchase price of such Pre-Settlement Shares
        hereunder; and provided further that the Company hereby acknowledges and agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not during the Pre-Settlement Period such Purchaser shall sell
        any shares of Common Stock to any Person and that any such decision to sell any shares of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect any such sale, if any. Notwithstanding anything to the
        contrary herein and a Purchaser&#8217;s Subscription Amount set forth on the signature pages attached hereto, the number of Shares purchased by a Purchaser (and its Affiliates) hereunder shall not, when aggregated with all other shares of Common Stock
        owned by such Purchaser (and its Affiliates) at such time, result in such Purchaser beneficially owning (as determined in accordance with Section 13(d) of the Exchange Act) in excess of 9.9% of the then issued and outstanding Common Stock
        outstanding at the Closing (the &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Beneficial Ownership Maximum</u></font>&#8221;), and such Purchaser&#8217;s Subscription Amount, to the extent it would otherwise exceed the Beneficial
        Ownership Maximum immediately prior to the Closing, shall be conditioned upon the issuance of Shares at the Closing to the other Purchasers signatory hereto. To the extent that a Purchaser&#8217;s beneficial ownership of the Shares would otherwise be
        deemed to exceed the Beneficial Ownership Maximum, such Purchaser&#8217;s Subscription Amount shall automatically be reduced as necessary in order to comply with this paragraph.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">2.2</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Deliveries</u></font>.</font></div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zc86e31aee69a4486b144b9d021e6cb2e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(a)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">On or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to
                each Purchaser the following:</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z33275dfc3b0e4d0ea8e7576a56cbe29d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(i)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">this Agreement duly executed by the Company;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="ze7025fa422324106a9ac69637c6bcda3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(ii)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">a legal opinion of Company Counsel, in form and substance reasonably satisfactory to the Placement Agent and
                Purchasers;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z5c17043bdef14399a9f2611bece35fea" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(iii)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">subject to the fifth sentence of Section 2.1, the Company shall have provided each Purchaser with the Company&#8217;s
                wire instructions, on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z36f42f50b64f4889a4f6336cd47dbe34" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(iv)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">subject to the fifth sentence of Section 2.1, a copy of the irrevocable instructions to the Transfer Agent
                instructing the Transfer Agent to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>DWAC</u></font>&#8221;) Shares
                equal to such Purchaser&#8217;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z0d91afc77ce14270b990f29250086c01" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(v)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">on the date hereof, the duly executed Lock-Up Agreements; and</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zaf58d37030714eb9b36a9f448a939db9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(vi)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities
                Act).</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z02f0313e99bf49e1a7138056d3489dc2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(b)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, as
                applicable, the following:</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z8255a22685aa4877bb358070c4defb85" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(i)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">this Agreement duly executed by such Purchaser; and</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z74d844216b6b4369a0a8bb12c759926e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(ii)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">such Purchaser&#8217;s Subscription Amount, which shall be made available for &#8220;Delivery Versus Payment&#8221; settlement with
                the Company or its designee.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">2.3</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Closing Conditions</u></font>.</font></div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; margin-bottom: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">(a)</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">The obligations of the Company hereunder in connection with the Closing are subject to the following
        conditions being met:</font></div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zffa3b91c42dd4d31ba0d15d9923d78d2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(i)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">the accuracy in all material respects (or, to the extent representations or warranties are qualified by
                materiality, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate (or, to the extent representations or
                warranties are qualified by materiality, in all respects) as of such date);</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zf3f484bae50143f78bf392dc4962a85d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(ii)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing
                Date shall have been performed; and</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z0b1df28fdd7748dab37607a0025da8d1" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(iii)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z8be516ce176c4cdb87cb890daa32d57d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(b)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following
                conditions being met:</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z1b42c85d4265402fb246c407333ca8ef" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(i)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">the accuracy in all material respects (or, to the extent representations or warranties are qualified by
                materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate in
                all material respects, or to the extent representations or warranties are qualified by materiality or Material Adverse effect, in all respects as of such date);</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z9f40c8e73c134dbf90496c21d24c3a36" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(ii)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date
                shall have been performed;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z9f051a0bf11d4e5a9befb90cdd8a14aa" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(iii)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="ze91faf6fa5084a818d47d9366c07db4c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(iv)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">there shall have been no Material Adverse Effect with respect to the Company;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zcd4f00f0923e40dda0b4d2be3a87c9e7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(v)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the
                Commission or the Company&#8217;s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been
                established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any
                material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such
                Purchaser, makes it impracticable or inadvisable to purchase the Shares at the Closing.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">ARTICLE III.</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font><font style="font-size: 10pt;">REPRESENTATIONS AND WARRANTIES</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">3.1</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Representations and Warranties of the Company</u></font>.&#160; Except as set
        forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding section of the Disclosure
        Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</font></div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z0d38951aecf64e00823a8827f65ef26e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(a)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Subsidiaries</u></font><font style="font-size: 10pt;">.&#160; All of the direct and indirect subsidiaries of the Company are set forth on <font style="font-family: 'Times New Roman',Times,serif;"><u>Schedule 3.1(a)</u></font>.&#160; The Company owns, directly or
                  indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid,
                  non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.&#160; If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be
                  disregarded.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z24f6d7c80aa84973968bc3e00d137753" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(b)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Organization and
                    Qualification</u></font><font style="font-size: 10pt;">.&#160; The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its
                  incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted.&#160; Neither the Company nor any Subsidiary is in violation nor default of any
                  of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents.&#160; Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as
                  a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the
                  case may be, would not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations,
                  assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&#8217;s ability to perform in any material respect on a timely basis its
                  obligations under any Transaction Document (any of (i), (ii) or (iii), a &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Material Adverse Effect</u></font>&#8221;) and no Proceeding has been instituted in any such
                  jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z97443905606448ecb7a6d86a33cbc5dc" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(c)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Authorization;
                    Enforcement</u></font><font style="font-size: 10pt;">.&#160; The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction
                  Documents and otherwise to carry out its obligations hereunder and thereunder.&#160; The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions
                  contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&#8217;s stockholders in connection herewith or
                  therewith other than in connection with the Required Approvals.&#160; This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in
                  accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and
                  applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance,
                  injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z134d204e4d4e4e4cb55d26f63a976b9a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(d)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>No Conflicts</u></font><font style="font-size: 10pt;">.&#160; The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the
                  transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company&#8217;s or any Subsidiary&#8217;s certificate or articles of incorporation, bylaws or other organizational or charter
                  documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any
                  Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other
                  instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii)
                  subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary
                  is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as would not have
                  or reasonably be expected to result in a Material Adverse Effect.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z57bd0299d50845b69503d5cff47dc68c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(e)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Filings, Consents
                    and Approvals</u></font><font style="font-size: 10pt;">.&#160; The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal,
                  state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to Section 4.3 of this
                  Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) application(s) to each applicable Trading Market for the listing of the Shares for trading thereon in the time and manner required thereby and (iv) such
                  filings as are required to be made under applicable state securities laws (collectively, the &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Required Approvals</u></font>&#8221;).</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zf37eec51b22d44ab815ddda65cbbbe94" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(f)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Issuance of the
                    Shares; Registration</u></font><font style="font-size: 10pt;">.&#160; The Shares are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and
                  nonassessable, free and clear of all Liens imposed by the Company.&#160; The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement. The Company has prepared
                  and filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective on&#160;February 14, 2023 (the &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Effective Date</u></font>&#8221;),
                  including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement.&#160; The Registration Statement is effective under the Securities Act and no stop order preventing or suspending
                  the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are
                  threatened by the Commission.&#160; The Company, if required by the rules and regulations of the Commission, shall file the Prospectus with the Commission pursuant to Rule 424(b).&#160; At the time the Registration Statement and any amendments
                  thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did
                  not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or
                  supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and will
                  not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company was at the
                  time of the filing of the Registration Statement eligible to use Form S-3. The Company is eligible to use Form S-3 under the Securities Act and it meets the transaction requirements with respect to the aggregate market value of securities
                  being sold pursuant to this offering and during the twelve (12) months prior to this offering, as set forth in General Instruction I.B.6 of Form S-3.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z14720dcb16f34738b1c8879d2277eb61" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(g)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Capitalization</u></font><font style="font-size: 10pt;">.&#160; The capitalization of the Company as of the date hereof is as set forth on <font style="font-family: 'Times New Roman',Times,serif;"><u>Schedule 3.1(g)</u></font>, which <font style="font-family: 'Times New Roman',Times,serif;"><u>Schedule 3.1(g)</u></font> shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof.&#160; Except as set forth
                  on <font style="font-family: 'Times New Roman',Times,serif;"><u>Schedule 3.1(g)</u></font>, the Company has not issued any capital stock since its <font style="font-family: 'Times New Roman',Times,serif;">most
                    recently filed periodic report under the Exchange Act, </font>other than pursuant to the exercise of employee stock options under the Company&#8217;s stock option plans, the issuance of shares of Common Stock to employees and consultants
                  pursuant to the Company&#8217;s stock incentive plans, pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act.&#160; No Person has any right
                  of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents.&#160; Except as set forth on <font style="font-family: 'Times New Roman',Times,serif;"><u>Schedule 3.1(g)</u></font>, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations
                  convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements
                  by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary.&#160; The issuance and sale of the Shares will not obligate the Company or
                  any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the
                  exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary.&#160; There are no outstanding securities or instruments of the Company or any Subsidiary that
                  contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary.
                  The Company does not have any stock appreciation rights or &#8220;phantom stock&#8221; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid
                  and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.&#160;
                  No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Shares.&#160; There are no stockholders agreements, voting agreements or other similar agreements with
                  respect to the Company&#8217;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&#8217;s stockholders.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z37a795d26e794b9f958828a8eadfec3c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(h)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>SEC Reports;
                    Financial Statements</u></font><font style="font-size: 10pt;">.&#160; The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act,
                  including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the
                  exhibits thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus Supplement, being collectively referred to herein as the &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>SEC Reports</u></font>&#8221;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension.&#160; As of their respective
                  dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or
                  omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company is an issuer subject to Rule
                  144(i) under the Securities Act; however,<font style="font-family: 'Times New Roman',Times,serif;"> &#160;i</font>t has filed current &#8220;Form 10 information&#8221; with the Commission reflecting its status as an entity that is no longer an
                  issuer described in paragraph (i)(1)(i) of Rule 144.&#160; The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the
                  Commission with respect thereto as in effect at the time of filing.&#160; Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods
                  involved (&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>GAAP</u></font>&#8221;), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may
                  not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows
                  for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z27fc939e9c66443ca59f42050a10944f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(i)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Material Changes;
                    Undisclosed Events, Liabilities or Developments</u></font><font style="font-size: 10pt;">.&#160; Since the date of the latest audited financial statements included within the SEC Reports, except as set forth on <font style="font-family: 'Times New Roman',Times,serif;"><u>Schedule 3.1(i)</u></font>, (i) there has been no event, occurrence or development that has had or that would reasonably be expected to result in a Material Adverse Effect, (ii) the Company
                  has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in
                  the Company&#8217;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of
                  cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate,
                  except pursuant to existing Company stock incentive plans.&#160; The Company does not have pending before the Commission any request for confidential treatment of information.&#160; Except for the issuance of the Shares contemplated by this
                  Agreement or as set forth on <font style="font-family: 'Times New Roman',Times,serif;"><u>Schedule 3.1(i)</u></font>, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably
                  expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under
                  applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z44fa87a267d745c6b2945665a248b0a8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(j)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Litigation</u></font><font style="font-size: 10pt;">.&#160;&#160; Except as set forth on <font style="font-family: 'Times New Roman',Times,serif;"><u>Schedule 3.1(j)</u></font>, there is no action, suit, inquiry, notice of violation, proceeding or investigation
                  pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory
                  authority (federal, state, county, local or foreign) (collectively, an &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Action</u></font>&#8221;).&#160; None of the Actions set forth on <font style="font-family: 'Times New Roman',Times,serif;"><u>Schedule 3.1(j)</u></font>, (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Shares or (ii) could, if there were an unfavorable
                  decision, have or reasonably be expected to result in a Material Adverse Effect.&#160; Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or
                  liability under federal or state securities laws or a claim of breach of fiduciary duty.&#160; There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the
                  Company or any current or former director or officer of the Company.&#160; The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the
                  Exchange Act or the Securities Act.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z6fb841a7a96141099175233123a5b67d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(k)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Labor Relations</u></font><font style="font-size: 10pt;">.&#160; No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could reasonably be expected to result in a Material Adverse Effect.&#160; None of
                  the Company&#8217;s or its Subsidiaries&#8217; employees is a member of a union that relates to such employee&#8217;s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective
                  bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good.&#160; To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to
                  be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of
                  any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters.&#160; The Company and its Subsidiaries are in
                  compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance would
                  not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z8795df802d3f427a921747bf4b6c3d11" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">(l)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Compliance</u></font><font style="font-size: 10pt;">.&#160; Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by
                  the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument
                  to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental
                  authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental
                  protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as would not have or reasonably be expected to result in a Material Adverse Effect.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zdc58da8286ab48aa9954fd96c346f35f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(m)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Environmental Laws</u>.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 144pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water,
                  groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Hazardous Materials</u></font>&#8221;) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or
                  handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated
                  or approved thereunder (&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Environmental Laws</u></font>&#8221;); (ii) have received all permits licenses or other approvals required of them under applicable Environmental
                  Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply would be reasonably expected
                  to have, individually or in the aggregate, a Material Adverse Effect.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z9fe1cbd39ea7463b9af86eaf27cb4bb4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(n)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Regulatory
                    Permits</u></font><font style="font-size: 10pt;">.&#160; The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to
                  conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits would not reasonably be expected to result in a Material Adverse Effect (&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Material Permits</u></font>&#8221;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zca54e470622e4130a48ce3b0dd67a0ce" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(o)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Title to Assets</u></font><font style="font-size: 10pt;">.&#160; The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the
                  business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made
                  of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither
                  delinquent nor subject to penalties.&#160; Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in
                  compliance.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zf3d31b3545cc49b18339bb273527c3a8" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(p)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Intellectual
                    Property</u></font><font style="font-size: 10pt;">.&#160; The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets,
                  inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have would
                  have a Material Adverse Effect (collectively, the &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Intellectual Property Rights</u></font>&#8221;).&#160; None of, and neither the Company nor any Subsidiary has received a
                  notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement, except as
                  would not reasonably be expected to have a Material Adverse Effect.&#160; Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a
                  claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as would not have or reasonably be expected to not have a Material Adverse Effect.&#160; To the knowledge of
                  the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights.&#160; The Company and its Subsidiaries have taken reasonable security
                  measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z91da71f544254fa4ab1f6b009ad1aac6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(q)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Insurance</u></font><font style="font-size: 10pt;">.&#160; The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the
                  Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage in the amount of $1,500,000.&#160; Neither the Company nor any Subsidiary has been advised that it will not be able to renew its
                  existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zb706cb3ad7de4bf59e39814335e13a67" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(r)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Transactions With
                    Affiliates and Employees</u></font><font style="font-size: 10pt;">.&#160; Except as set forth on <font style="font-family: 'Times New Roman',Times,serif;"><u>Schedule 3.1(r)</u></font>, none of the officers or directors of the
                  Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees,
                  officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or
                  lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an
                  officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the
                  Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zd72464f4a8f7496ba1d457c5bcfe6628" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(s)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Sarbanes-Oxley;
                    Internal Accounting Controls</u></font><font style="font-size: 10pt;">.&#160; The Company and the Subsidiaries are in compliance in all material respects with any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended,
                  that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date.&#160; <font style="font-family: 'Times New Roman',Times,serif;">Except as disclosed in <u>Schedule 3.1(s)</u>, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or
                    specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with
                    management&#8217;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as
                    disclosed in <u>Schedule 3.1(s)</u>, the Company and the Subsidiaries have
                    established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to
                    be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms.&#160; The Company&#8217;s certifying
                    officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date,
                    the &#8220;<u>Evaluation Date</u>&#8221;).&#160; The Company presented in its most recently filed
                    periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date.&#160; Since the Evaluation Date, there
                    have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the
                    internal control over financial reporting of the Company and its Subsidiaries.</font></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="ze073a77ab2954167ace4bb784785520a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(t)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Certain Fees</u></font><font style="font-size: 10pt;">.&#160; Except for fees payable by the Company to the Placement Agent, no brokerage or finder&#8217;s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or
                  consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents.&#160; The Purchasers shall have no obligation with respect to any fees or with respect to
                  any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z5623c53a620b42a2be4f89443a88e462" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(u)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Investment
                    Company</u></font><font style="font-size: 10pt;">. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares, will not be or be an Affiliate of, an &#8220;investment company&#8221; within the meaning of
                  the Investment Company Act of 1940, as amended.&#160; The Company shall conduct its business in a manner so that it will not become an &#8220;investment company&#8221; subject to registration under the Investment Company Act of 1940, as amended.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z0e5deb0543144b91bb3c5f6abd4c1623" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(v)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Registration
                    Rights</u></font><font style="font-size: 10pt;">.&#160; No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z6ba8e672ea8a4d74a7b9205fefef8238" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(w)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Listing and
                    Maintenance Requirements</u></font><font style="font-size: 10pt;">.&#160; The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is
                  likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration.&#160; The Company has not,
                  in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements
                  of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for
                  electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in
                  connection with such electronic transfer.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z99806001f1a042f48e846dbc0cb81eee" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(x)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Application of
                    Takeover Protections</u></font><font style="font-size: 10pt;">.&#160; The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison
                  pill (including any distribution under a rights agreement) or other similar anti&#8209;takeover provision under the Company&#8217;s certificate of incorporation (or similar charter documents) or the laws of its state of incorporation that is or would
                  become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&#8217;s issuance
                  of the Shares and the Purchasers&#8217; ownership of the Shares.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zc90ec457613f4af7a5890b29909dd1f9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(y)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Disclosure</u></font><font style="font-size: 10pt;">.&#160; Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has
                  provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in, or incorporated by reference into, the
                  Prospectus Supplement.&#160;&#160; The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company.&#160; All of the disclosure furnished by or on behalf of the
                  Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct and does not contain any
                  untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated
                  by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to
                  make the statements therein, in the light of the circumstances under which they were made and when made, not misleading.&#160; The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with
                  respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zfbadba0363bd447287e67b94dd0d54a3" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(z)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>No Integrated
                    Offering</u></font><font style="font-size: 10pt;">. Assuming the accuracy of the Purchasers&#8217; representations and warranties set forth in Section 3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their
                  behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Shares to be integrated with prior offerings by the
                  Company for purposes of any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zfb89c0a0886c49b7ae7cd03f39013660" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(aa)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Solvency</u></font><font style="font-size: 10pt;">.&#160; Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Shares hereunder, (i) the fair
                  saleable value of the Company&#8217;s assets exceeds the amount that will be required to be paid on or in respect of the Company&#8217;s existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company&#8217;s
                  assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by
                  the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets,
                  after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid.&#160; The Company does not intend to incur debts beyond its
                  ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt).&#160; The Company has no knowledge of any facts or circumstances which lead it to believe that it will
                  file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date.&#160; <font style="font-family: 'Times New Roman',Times,serif;"><u>Schedule 3.1(aa)</u></font>
                  sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments.&#160; For the purposes of this Agreement, &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Indebtedness</u></font>&#8221; means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary
                  course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&#8217;s consolidated balance sheet (or the notes
                  thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under
                  leases required to be capitalized in accordance with GAAP.&#160; Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z1f229f42d4ed4c008d1a729f6ff1986e" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(bb)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Tax Status</u></font><font style="font-size: 10pt;">.&#160; Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United
                  States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges
                  that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the
                  periods to which such returns, reports or declarations apply.&#160; There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
                  basis for any such claim.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z2fe8a3fec9024d7b955346fa0903aaa0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(cc)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Foreign Corrupt
                    Practices</u></font><font style="font-size: 10pt;">.&#160; Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i)
                  directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government
                  officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of
                  which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z8ef436cb6db943d580f12a529d532346" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(dd)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Accountants</u></font><font style="font-size: 10pt;">.&#160; The Company&#8217;s accounting firm is Marcum LLP.&#160; To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express
                  its opinion with respect to the financial statements to be included in the Company&#8217;s Annual Report for the fiscal year ending December 31, 2023.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z11814197d71d430d8151cdb936cec6f5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(ee)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">&#160;<font style="font-family: 'Times New Roman',Times,serif;"><u>Acknowledgment Regarding Purchasers&#8217;
                    Purchase of Shares</u></font>.&#160; The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm&#8217;s length purchaser with respect to the Transaction Documents and the transactions contemplated
                thereby.&#160; The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and
                any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers&#8217; purchase of the Shares.&#160;
                The Company further represents to each Purchaser that the Company&#8217;s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the
                Company and its representatives.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zebc299da602e41c4b1223812d1210f62" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(ff)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Acknowledgment
                    Regarding Purchaser&#8217;s Trading Activity</u>.&#160; Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections
                  3.2 (f) and 4.12 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short,
                  securities of the Company, or &#8220;derivative&#8221; securities based on securities issued by the Company or to hold the </font><font style="font-size: 10pt;">Shares<font style="font-family: 'Times New Roman',Times,serif;"> for any
                    specified term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &#8220;derivative&#8221; transactions, before or after the closing of this or future private
                    placement transactions, may negatively impact the market price of the Company&#8217;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &#8220;derivative&#8221; transactions to which any such Purchaser is a party, directly or
                    indirectly, presently may have a &#8220;short&#8221; position in the Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&#8217;s length counter-party in any &#8220;derivative&#8221; transaction.&#160; </font>The
                  Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the Shares are outstanding, and (z) such hedging activities (if any) could reduce the
                  value of the existing stockholders' equity interests in the Company at and after the time that the hedging activities are being conducted.&#160; The Company acknowledges that such aforementioned hedging activities do not constitute a breach of
                  any of the Transaction Documents.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z1ab3c12cec5148d38c42437537f7b8a0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(gg)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Regulation M
                    Compliance</u></font><font style="font-size: 10pt;">.&#160; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or
                  manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Shares, or (iii) paid or
                  agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the
                  placement of the Shares.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z657159b2eba44cb4bdf879faa6a95939" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(hh)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>FDA</u></font><font style="font-size: 10pt;">.&#160; As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>FDA</u></font>&#8221;) under the Federal Food, Drug and
                  Cosmetic Act, as amended, and the regulations thereunder (&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>FDCA</u></font>&#8221;) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the
                  Company or any of its Subsidiaries (each such product, a &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Pharmaceutical Product</u></font>&#8221;), such Pharmaceutical Product is being manufactured, packaged, labeled,
                  tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or
                  application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance
                  would not have a Material Adverse Effect.&#160; There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or
                  investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i)
                  contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii)
                  withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any
                  clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the
                  Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse
                  Effect.&#160; The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA.&#160; The Company has not been informed by the
                  FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for
                  marketing any product being developed or proposed to be developed by the Company.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="za4692b498b584f6c9b0f6372e2e97773" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(ii)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Stock Option
                    Plans</u></font><font style="font-size: 10pt;">. Each stock option granted by the Company under the Company&#8217;s stock option plan was granted (i) in accordance with the terms of the Company&#8217;s stock option plan and (ii) with an exercise
                  price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company&#8217;s stock option plan has been backdated.&#160;
                  The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public
                  announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z878f275e445c45f6b960996f8d902922" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(jj)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Cybersecurity</u></font><font style="font-size: 10pt;">.&#160; (i)(x) <font style="font-family: 'Times New Roman',Times,serif;">T</font>here has been no security breach or other compromise of or relating to any of the Company&#8217;s or any Subsidiary&#8217;s information
                  technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology
                  (collectively, &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>IT Systems and Data</u></font>&#8221;) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition
                  that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments,
                  orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT
                  Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)&#160;the Company and the Subsidiaries have implemented and
                  maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the
                  Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z14ae696d22654c5bbb960c946e106bc6" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(kk)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Office of Foreign
                    Assets Control</u></font><font style="font-size: 10pt;">.&#160; Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject
                  to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>OFAC</u></font>&#8221;).</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z560e124b88884f9ba77f0cba5901a8dd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(ll)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>U.S. Real
                    Property Holding Corporation</u></font><font style="font-size: 10pt;">.&#160; The Company is not and has never been a U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended,
                  and the Company shall so certify upon Purchaser&#8217;s request.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="za5accc0b5ff54cc7a9d75072655b4ad0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(mm)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 108pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Bank Holding
                    Company Act</u></font><font style="font-size: 10pt;">.&#160; Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>BHCA</u></font>&#8221;) and to regulation by the Board of Governors of the Federal Reserve System (the &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Federal Reserve</u></font>&#8221;).&#160; Neither
                  the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a
                  bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.&#160; Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any
                  entity that is subject to the BHCA and to regulation by the Federal Reserve.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z0b3b787f01ac4fbcbc8637cd97112564" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(nn)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Money Laundering</u></font><font style="font-size: 10pt;">.&#160; The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign
                  Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Money
                      Laundering Laws</u></font>&#8221;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending
                  or, to the knowledge of the Company or any Subsidiary, threatened.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">3.2</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Representations and Warranties of the Purchasers</u></font>.&#160; Each Purchaser,
        for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date):</font></div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zf52127f1daf84edc86db19c7b4fd94a0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 21pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(a)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 87pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Organization;
                    Authority</u></font><font style="font-size: 10pt;">.&#160; Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or
                  formation with full right, corporate, partnership limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its
                  obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary
                  corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser.&#160; Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such
                  Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and
                  applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance,
                  injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z1be9bfbcdc7f476dae3d55856ae58c68" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 21pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(b)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 87pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Understandings or
                    Arrangements</u></font><font style="font-size: 10pt;">.&#160; Such Purchaser is acquiring the Shares as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or
                  regarding the distribution of such Shares (this representation and warranty not limiting such Purchaser&#8217;s right to sell the Shares pursuant to the Registration Statement or otherwise in compliance with applicable federal and state
                  securities laws).&#160; Such Purchaser is acquiring the Shares hereunder in the ordinary course of its business.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z615bf2990dcc450d95f51c1c44fd21d0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 21pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(c)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 87pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Purchaser Status</u></font><font style="font-size: 10pt;">.&#160; At the time such Purchaser was offered the Shares, it was, and as of the date hereof it is an &#8220;accredited investor&#8221; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) under
                  the Securities Act.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zbc36545349ab4bca9a27adbe0c0e7ee9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 21pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(d)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 87pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Experience of
                    Such Purchaser</u></font><font style="font-size: 10pt;">.&#160; Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of
                  evaluating the merits and risks of the prospective investment in the Shares, and has so evaluated the merits and risks of such investment.&#160; Such Purchaser is able to bear the economic risk of an investment in the Shares and, at the
                  present time, is able to afford a complete loss of such investment.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z44d28920b7c44766b1acde01df1c3cdf" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 21pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(e)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 87pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Access to
                    Information</u></font><font style="font-size: 10pt;">. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports and has been
                  afforded, (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Shares and the merits and risks of
                  investing in the Shares; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the
                  opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.&#160; Such Purchaser
                  acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the Shares nor is such information or advice necessary or
                  desired.&#160; Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Shares and the Placement Agent and any Affiliate may have acquired non-public information with respect to
                  the Company which such Purchaser agrees need not be provided to it.&#160; In connection with the issuance of the Shares to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to
                  such Purchaser.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z43e7f910136844bfbe989d28d7e097a9" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 12pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 21pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; margin-left: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">(f)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; text-indent: 87pt; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Certain
                    Transactions and Confidentiality</u></font><font style="font-size: 10pt;">.&#160; Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any
                  understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales,&#160;of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet
                  (written or oral) from the Placement Agent, the Company or any other Person representing the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof.
                  Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct
                  knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio
                  manager that made the investment decision to purchase the Shares covered by this Agreement.&#160; Other than to other Persons party to this Agreement or to such Purchaser&#8217;s representatives, including, without limitation, its officers,
                  directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of
                  this transaction).&#160;&#160; Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to
                  effect Short Sales or similar transactions in the future.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">The Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect
      such Purchaser&#8217;s right to rely on the Company&#8217;s representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered
      in connection with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
      with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">ARTICLE IV.</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font><font style="font-size: 10pt;">OTHER AGREEMENTS OF THE PARTIES</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.1</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Furnishing of Information</u></font>.&#160; Until the
        earlier of (i) one year from the Closing Date or (ii) the time that no Purchaser owns Shares, the Company covenants to use reasonable best efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace period)
        all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act but only so long as the Company is then subject to the reporting requirements of the Exchange Act.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.2</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Integration</u></font>.&#160; The Company shall not sell,
        offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Shares for purposes of the rules and regulations of any
        Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.3</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Securities Laws Disclosure; Publicity</u></font>.&#160;
        The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the
        Commission within the time required by the Exchange Act.&#160; From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the
        Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, in connection with the transactions contemplated by the
        Transaction Documents.&#160; In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company,
        any of its Subsidiaries or any of their respective officers, directors, agents, employees, Affiliates or agents, including without limitation, the Placement Agent, on the one hand, and any of the Purchasers or any of their Affiliates on the other
        hand, shall terminate and be of no further force or effect. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser
        shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement
        without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or
        delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication.&#160; Notwithstanding the foregoing, the Company shall not
        publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal
        securities law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with
        prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.4</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Shareholder Rights Plan</u></font>.&#160; No claim will be
        made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Acquiring Person</u></font>&#8221; under any control share
        acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the
        provisions of any such plan or arrangement, by virtue of receiving Shares under the Transaction Documents or under any other agreement between the Company and the Purchasers.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.5</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Non-Public Information</u></font>.&#160; Except with
        respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be disclosed pursuant to Section 4.3, the Company covenants and agrees that neither it, nor any other Person acting on its
        behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing
        to the receipt of such information and agreed in writing with the Company to keep such information confidential.&#160; The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in
        securities of the Company.&#160; To the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, employees or Affiliates delivers any material, non-public information to a Purchaser without such Purchaser&#8217;s
        consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including,
        without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors,&#160; employees, Affiliates or agents including, without limitation, the Placement Agent, not to trade on the
        basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public
        information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant to a Current Report on Form 8-K.&#160; The Company understands and confirms that each
        Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">4.6</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Use of Proceeds</u></font>.&#160; Except
        as set forth on <font style="font-family: 'Times New Roman',Times,serif;"><u>Schedule 4.6</u></font> attached hereto, the Company shall use the net proceeds from the sale of the Shares hereunder for working capital purposes and shall not
        use such proceeds: (a) for the satisfaction of any portion of the Company&#8217;s debt (other than payment of trade payables in the ordinary course of the Company&#8217;s business and prior practices), (b) for the redemption of any Common Stock or Common Stock
        Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.7</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Indemnification of Purchasers</u></font>.&#160;&#160; Subject
        to the provisions of this Section 4.7, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person
        holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers,
        shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &#8220;<font style="font-family: 'Times New Roman',Times,serif;"><u>Purchaser Party</u></font>&#8221;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
        settlements, court costs and reasonable attorneys&#8217; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements
        made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an
        Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such&#160; Purchaser Party&#8217;s representations, warranties or covenants
        under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which
        is finally judicially determined to constitute fraud, gross negligence or willful misconduct.&#160; If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party
        shall promptly notify the Company in writing, and, the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party.&#160; Any Purchaser Party shall have the right to employ one
        separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically
        authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel a material conflict on any
        material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel.&#160; The Company will not be
        liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&#8217;s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent
        that a loss, claim, damage or liability is attributable to any Purchaser Party&#8217;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents.&#160; The
        indemnification required by this Section 4.7 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred, provided that the Purchaser Party executes an
        undertaking to reimburse the amounts paid if indemnification is unavailable hereunder.&#160; The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and
        any liabilities the Company may be subject to pursuant to law.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.8</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>L</u><u>isting of Common Stock</u></font>. The Company hereby agrees to use reasonable best efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and prior to
        or concurrently with the Closing, the Company shall apply to list or quote all of the Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then
        include in such application all of the Shares, and will take such other action as is necessary to cause all of the Shares to be listed or quoted on such other Trading Market as promptly as possible.&#160; The Company will then take all action reasonably
        necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&#8217;s reporting, filing and other obligations under the bylaws or rules of the Trading Market.&#160; For so long as the
        Company maintains a listing or quotation of the Common Stock on a Trading Market, the Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing
        corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.9</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Reserved</u></font>.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.10</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Reserved.</u></font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.11</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Equal Treatment of Purchasers</u></font>.&#160; No consideration (including any
        modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties to
        such Transaction Document.&#160; For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a
        class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Shares or otherwise.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.12</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Certain Transactions and Confidentiality</u>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will
          execute any purchases or sales, including Short Sales of any of the Company&#8217;s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first
          publicly announced pursuant to the initial press release as described in Section 4.3.</font>&#160; <font style="font-family: 'Times New Roman',Times,serif;">Each Purchaser, severally and not jointly with the other Purchasers, covenants that
          until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.3, such Purchaser will maintain the confidentiality of the existence and
          terms of this transaction and the information included in the Disclosure Schedules (other than as disclosed to its legal and other representatives).&#160; N</font>otwithstanding the foregoing, and notwithstanding anything contained in this Agreement
        to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the
        transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.3, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the
        Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.3 and (iii) no Purchaser
        shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company, any of&#160; its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agent, including without limitation, the
        Placement Agent, after the issuance of the initial press release as described in Section 4.3.&#160; <font style="font-family: 'Times New Roman',Times,serif;">Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed
          investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of
          such Purchaser&#8217;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Shares covered by this Agreement.</font></font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.13</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>Reserved.</u></font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">4.14</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Lock-Up Agreements</u></font>. The Company shall not amend, modify, waive or
        terminate any provision of any of the Lock-Up Agreements except to extend the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If any party to a Lock-Up Agreement breaches any
        provision of a Lock-Up Agreement, the Company shall promptly use its reasonable best efforts to seek specific performance of the terms of such Lock-Up Agreement.</font></div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">ARTICLE V.</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><br>
      </font><font style="font-size: 10pt;">MISCELLANEOUS</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.1</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Termination</u></font>.&#160; This Agreement may be
        terminated by any Purchaser, as to such Purchaser&#8217;s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been
        consummated on or before the fifth (5<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) Trading Day following the date hereof; <font style="font-family: 'Times New Roman',Times,serif;"><u>provided</u></font>, <font style="font-family: 'Times New Roman',Times,serif;"><u>however</u></font>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.2</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Fees and Expenses</u></font>.&#160; Except as expressly
        set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
        preparation, execution, delivery and performance of this Agreement.&#160; The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company), stamp
        taxes and other taxes and duties levied in connection with the delivery of any Shares to the Purchasers.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.3</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Entire Agreement</u></font>.&#160; The Transaction
        Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and
        understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.4</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Notices</u></font>.&#160; Any and all notices or other
        communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email
        attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is
        delivered via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup>) Trading Day
        following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given.&#160; The address for such notices and communications shall be as set
        forth on the signature pages attached hereto.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.5</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Amendments; Waivers</u></font>.&#160; No provision of this
        Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on the initial Subscription
        Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver
        disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required.&#160; No waiver of any default with respect to any provision,
        condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any
        party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the
        comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of
        Shares and the Company.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.6</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Headings</u></font>.&#160; The headings herein are for
        convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.7</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Successors and Assigns</u></font>.&#160; This Agreement
        shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.&#160; The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other
        than by merger).&#160; Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Shares, provided that such transferee agrees in writing to be bound, with respect to the
        transferred Shares, by the provisions of the Transaction Documents that apply to the &#8220;Purchasers.&#8221;</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.8</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>No Third-Party Beneficiaries</u></font>.&#160; The
        Placement Agent shall be the third party beneficiary of the representations and warranties of the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2.&#160; This Agreement is intended for the benefit of the
        parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.7 and this Section 5.8.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.9</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Governing Law</u></font>.&#160; All questions concerning
        the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
        law thereof.&#160; Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its
        respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.&#160; Each party hereby irrevocably submits to the
        exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein
        (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court,
        that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding.&#160; Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy
        thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of
        process and notice thereof.&#160; Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.&#160;&#160; If any party shall commence an Action or Proceeding to enforce any provisions of the
        Transaction Documents, then, in addition to the obligations of the Company under Section 4.7, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&#8217; fees and other costs and
        expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.10</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Survival</u></font>.&#160; The representations and
        warranties contained herein shall survive the Closing and the delivery of the Shares.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.11</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Execution</u>.&#160; This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed
          by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart.&#160; In the event that any signature is delivered by e-mail delivery of a &#8220;.pdf&#8221; format data file (including any electronic
          signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com), such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such &#8220;.pdf&#8221;
          signature page were an original thereof.</font></font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.12</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Severability</u></font>.&#160; If any term, provision,
        covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and
        effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that
        contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
        of such that may be hereafter declared invalid, illegal, void or unenforceable.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.13</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Rescission and Withdrawal Right</u></font>.&#160;
        Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the
        Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or
        election in whole or in part without prejudice to its future actions and rights.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.14</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Replacement of Shares</u></font>.&#160; If any certificate
        or instrument evidencing any Shares is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution
        therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction.&#160; The applicant for a new certificate or instrument under such circumstances shall also pay any
        reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Shares.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.15</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Remedies</u></font>.&#160; In addition to being entitled
        to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents.&#160; The parties agree that monetary damages may
        not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense
        that a remedy at law would be adequate.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.16</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Payment Set Aside</u></font>.&#160; To the extent that the
        Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof
        are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law
        (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and
        continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.17</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Independent Nature of Purchasers&#8217; Obligations and
            Rights</u></font>.&#160; The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
        of the obligations of any other Purchaser under any Transaction Document.&#160; Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers
        as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the
        Transaction Documents.&#160; Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be
        necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.&#160; Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents.&#160; For
        reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through EGS.&#160; EGS does not represent any of the Purchasers and only represents the Placement Agent.&#160; The Company has
        elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers.&#160; It is expressly understood and agreed that each
        provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.18</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Saturdays, Sundays, Holidays, etc.</u>&#160; If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
        succeeding Business Day.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">5.19</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Construction</u></font>. The parties agree that each
        of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
        not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
        and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</font></div>
    <div style="margin-bottom: 12pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">5.20</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 10pt; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><font style="font-family: 'Times New Roman',Times,serif;"><u>WAIVER OF JURY TRIAL</u></font>.&#160;
        <font style="font-family: 'Times New Roman',Times,serif;"><u>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT
            PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</u></font></font></div>
    <div style="margin-bottom: 12pt; font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic;">(Signature Pages Follow)</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed
      by their respective authorized signatories as of the date first indicated above.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z3226da9402e24522a6b59b28403e5a4f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 61.28%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">BIORESTORATIVE THERAPIES, INC.</div>
            <div style="font-size: 10pt;">&#160;</div>
            <div style="font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 38.72%; vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Address for Notice:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 61.28%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">By:__________________________________________</div>
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;Name: Lance Alstodt</div>
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;Title: Chief Executive Officer</div>
            <div style="font-size: 10pt;">&#160;</div>
            <div style="font-size: 10pt;">&#160;</div>
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">With a copy to (which shall not constitute notice):</div>
            <div style="font-size: 10pt;">&#160;</div>
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Certilman Balin Adler &amp; Hyman, LLP</div>
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">90 Merrick Avenue</div>
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">East Meadow, New York 11554</div>
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Attention: Fred Skolnik, Esq.</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Email: fskolnik@certilmanbalin.com&#160;</font></div>
            <div style="font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 38.72%; vertical-align: top;">
            <div style="text-align: left; text-indent: -36pt; margin-left: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">BioRestorative Therapies, Inc.</div>
            <div style="text-align: left; text-indent: -36pt; margin-left: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">40 Marcus Drive, Suite One</div>
            <div style="text-align: left; text-indent: -36pt; margin-left: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Melville, New York 11747</div>
            <div style="text-align: left; text-indent: -36pt; margin-left: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Attention: Lance Alstodt,</div>
            <div style="text-align: left; text-indent: -36pt; margin-left: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Chief Executive Officer</div>
            <div style="text-align: left; text-indent: -36pt; margin-left: 36pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Email: <font style="font-family: 'Times New Roman',Times,serif;">lalstodt@biorestorative.com</font></div>
            <div style="font-size: 10pt;">&#160;</div>
            <div style="font-size: 10pt;">&#160;</div>
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> </font><font style="font-size: 10pt;">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 61.28%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 38.72%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">[PURCHASER SIGNATURE PAGES TO BRTX SECURITIES PURCHASE AGREEMENT]</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 24pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by
      their respective authorized signatories as of the date first indicated above.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Name of Purchaser: ________________________________________________________</div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Signature of Authorized Signatory of Purchaser</font><font style="font-size: 10pt;">: _________________________________</font></div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Name of Authorized Signatory: _______________________________________________</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Title of Authorized Signatory: ________________________________________________</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Email Address of Authorized Signatory:_________________________________________</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Address for Notice to Purchaser:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Address for Delivery of Shares to Purchaser (if not same as address for notice):</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Subscription Amount: $_________________</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Shares: _________________</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">EIN Number: ____________________</div>
    <div style="text-align: justify; font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#9633;</font><font style="font-size: 10pt;">&#160; Notwithstanding anything contained in
        this Agreement to the contrary, by checking this box (i) the obligations of the above-signed<font style="font-family: 'Times New Roman',Times,serif;">&#160;</font>to purchase the securities set forth in this Agreement to be purchased from the
        Company by the above-signed, and the obligations of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii) the Closing shall occur on the second (2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup>)
        Trading Day following the date of this Agreement and (iii) any condition to Closing contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed of any agreement,
        instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument,
        certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">[SIGNATURE PAGES CONTINUE]</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>ex10_2.htm
<DESCRIPTION>PLACEMENT AGENCY AGREEMENT BETWEEN COMPANY AND PLACEMENT AGENT
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Certilman Balin Adler & Hyman, LLP
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>Exhibit 10.2<br>
  </div>
  <div> <br>
  </div>
  <div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">PLACEMENT AGENCY AGREEMENT</div>
    <div><br>
    </div>
    <div style="text-align: right; text-indent: 36pt; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">[___, 2023</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">BioRestorative Therapies, Inc.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">40 Marcus Drive, Suite One</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Melville, New York 11747</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Attention: Lance Alstodt, President and Chief Executive Officer</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dear Mr. <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Alstodt</font>:</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This agreement (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Agreement</font>&#8221;)
      constitutes the agreement between Titan Partners Group LLC, a division of American Capital Partners, LLC (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Placement Agent</font>&#8221;) and <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">BioRestorative Therapies, Inc.</font>, a Nevada corporation (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Company</font>&#8221;),
      pursuant to which the Placement Agent shall serve as the exclusive placement agent for the Company, on a &#8220;reasonable best efforts&#8221; basis, in connection with the proposed placement (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Placement</font>&#8221;) of registered shares of common stock <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Shares</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8221;) of the Company, par value $0.0001 per share (the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Common Stock</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8221;)</font>.&#160; The terms of the Placement and the Shares shall be mutually agreed upon by the Company and the purchasers
      (each, a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Purchaser</font>&#8221; and collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Purchasers</font>&#8221;)
      and nothing herein constitutes that the Placement Agent would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Shares or complete the Placement.&#160; This Agreement and the documents executed
      and delivered by the Company and the Purchasers in connection with the Placement, including but not limited to the Purchase Agreement (as defined below), shall be collectively referred to herein as the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Transaction</font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Documents</font>.&#8221;&#160; The date of the closing of the Placement shall be referred
      to herein as the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Closing Date</font>.&#8221; The Company expressly acknowledges and agrees that
      the Placement Agent&#8217;s obligations hereunder are on a reasonable best-efforts basis only and that the execution of this Agreement does not constitute a commitment by the Placement Agent to purchase the Shares and does not ensure the successful
      placement of the Shares or any portion thereof or the success of the Placement Agent with respect to securing any other financing on behalf of the Company.&#160; The Placement Agent may retain other brokers or dealers to act as sub-agents or selected
      dealers on its behalf in connection with the Placement.&#160; The sale of the Shares to any Purchaser will be evidenced by a securities purchase agreement (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Purchase</font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Agreement</font>&#8221;) between the Company and such Purchaser in a form reasonably acceptable to the Company and the Placement Agent.
      Capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Purchase Agreement.&#160; Prior to the signing of any Purchase Agreement, officers of the Company will be available to answer inquiries from prospective
      Purchasers.</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>SECTION 1.</u></font><font style="width: 9pt; font-size: 1px; display: inline-block;" class="HorizontalTab"> &#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>REPRESENTATIONS
            AND WARRANTIES OF THE COMPANY; COVENANTS OF THE COMPANY</u></font>.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">A.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Representations of the Company</u></font>.&#160;
        Each of the representations and warranties (together with any related disclosure schedules thereto) and covenants made by the Company to the Purchasers in the Purchase Agreement in connection with the Placement is hereby incorporated herein by
        reference into this Agreement (as though fully restated herein) and is, as of the date of this Agreement and as of the Closing Date, hereby made to, and in favor of, the Placement Agent. In addition to the foregoing, the Company represents and
        warrants that:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">1.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">The Company has prepared and filed with the U.S. Securities and
          Exchange Commission (the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Commission</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221;) a
          registration statement on Form S-3 (Registration No. 333-269631), and amendments thereto, and related preliminary prospectuses, for the registration under the Securities Act of 1933, as amended (the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Securities Act</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221;), of the </font>Shares<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">, which registration statement, as so amended (including post-effective amendments, if any) became effective on February 14, 2023.&#160; At the time of such filing, the Company met the
          requirements of Form S-3 under the Securities Act. Such registration statement meets the requirements set forth in Rule 415(a)(1)(x) under the Securities Act and complies with said Rule. The Company will file with the Commission pursuant to Rule
          424(b) under the Securities Act, and the rules and regulations (the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Rules and Regulations</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221;) of the Commission promulgated thereunder, a supplement to the form of prospectus included in such registration statement relating to the placement of the </font>Shares<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> and the plan of distribution thereof and has advised the Placement Agent of all further information (financial and other) with respect to the Company required to be
          set forth therein. Such registration statement, including the exhibits thereto, as amended at the date of this Agreement, is hereinafter called the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Registration Statement</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221;; such prospectus in the form in which it appears in the Registration Statement is hereinafter called the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Base Prospectus</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221;; and the supplemented form of
          prospectus, in the form in which it will be filed with the Commission pursuant to Rule 424(b) (including the Base Prospectus as so supplemented) is hereinafter called the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Prospectus Supplement</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">.&#8221; Any reference in this Agreement to the Registration Statement, the Base Prospectus or
          the Prospectus Supplement shall be deemed to refer to and include the documents incorporated by reference therein (the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Incorporated
          Documents</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221;) pursuant to Item 12 of Form S-3 which were filed under the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Exchange Act</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221;) on or before the date of this Agreement, or the issue date
          of the Base Prospectus or the Prospectus Supplement, as the case may be; and any reference in this Agreement to the terms &#8220;amend,&#8221; &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect to the Registration Statement, the Base Prospectus or the Prospectus
          Supplement shall be deemed to refer to and include the filing of any document under the Exchange Act after the date of this Agreement, or the issue date of the Base Prospectus or the Prospectus Supplement, as the case may be, deemed to be
          incorporated therein by reference. All references in this Agreement to financial statements and schedules and other information which is &#8220;contained,&#8221; &#8220;included,&#8221; &#8220;described,&#8221; &#8220;referenced,&#8221; &#8220;set forth&#8221; or &#8220;stated&#8221; in the Registration Statement,
          the Base Prospectus or the Prospectus Supplement (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference
          in the Registration Statement, the Base Prospectus or the Prospectus Supplement, as the case may be. No stop order suspending the effectiveness of the Registration Statement or the use of the Base Prospectus or the Prospectus Supplement has been
          issued, and no proceeding for any such purpose is pending or has been initiated or, to the Company's knowledge, is threatened by the Commission. For purposes of this Agreement, &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">free writing prospectus</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221; has the meaning set forth in Rule 405 under the Securities Act and the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Time of Sale Prospectus</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221; means the preliminary
          prospectus, if any, together with the free writing prospectuses, if any, used in connection with the Placement, including any documents incorporated by reference therein.</font></font></div>
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">2.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">The Registration Statement (and any further documents to be filed with the Commission) contains all exhibits and schedules as required by the
        Securities Act. Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material respects with the Securities Act and the Exchange Act and the applicable Rules and Regulations
        and did not and, as amended or supplemented, if applicable, will not, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The
        Base Prospectus, the Time of Sale Prospectus and the Prospectus Supplement, each as of its respective date, comply in all material respects with the Securities Act and the Exchange Act and the applicable Rules and Regulations. Each of the Base
        Prospectus, the Time of Sale Prospectus and the Prospectus Supplement, as amended or supplemented, did not and will not contain as of the date thereof any untrue statement of a material fact or omit to state a material fact necessary in order to
        make the statements therein, in the light of the circumstances under which they were made, not misleading. The Incorporated Documents, when they were filed with the Commission, conformed in all material respects to the requirements of the Exchange
        Act and the applicable Rules and Regulations, and none of such documents, when they were filed with the Commission, contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein (with
        respect to Incorporated Documents incorporated by reference in the Base Prospectus or Prospectus Supplement), in the light of the circumstances under which they were made not misleading; and any further documents so filed and incorporated by
        reference in the Base Prospectus, the Time of Sale Prospectus or Prospectus Supplement, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and the applicable Rules and
        Regulations, as applicable, and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. No
        post-effective amendment to the Registration Statement reflecting any facts or events arising after the date thereof which represent, individually or in the aggregate, a fundamental change in the information set forth therein is required to be
        filed with the Commission. There are no documents required to be filed with the Commission in connection with the transaction contemplated hereby that (x) have not been filed as required pursuant to the Securities Act or (y) will not be filed
        within the requisite time period. There are no contracts or other documents required to be described in the Base Prospectus, the Time of Sale Prospectus or Prospectus Supplement, or to be filed as exhibits or schedules to the Registration
        Statement, which (x) have not been described or filed as required or (y) will not be filed within the requisite time period.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Reserved.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">There are no affiliations with any FINRA member firm among the Company's officers, directors or, to the knowledge of the Company, any ten percent (10.0%) or greater stockholder
        of the Company, except as set forth in the Registration Statement and the other documents the Company has filed or furnished with the Commission.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">B.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Covenants of the Company</u>. </font>The Company has delivered, or will as promptly as practicable deliver, to the Placement Agent materially complete conformed copies of the Registration Statement and of each
        consent and certificate of experts, as applicable, filed as a part thereof, and conformed copies of the Registration Statement (without exhibits), the Base Prospectus, the Time of Sale Prospectus and the Prospectus Supplement, as amended or
        supplemented, in such quantities and at such places as the Placement Agent reasonably requests. Neither the Company nor any of its directors and officers has distributed and none of them will distribute, prior to the Closing Date, any offering
        material in connection with the offering and sale of the Shares pursuant to the Placement other than the Base Prospectus, the Time of Sale Prospectus, the Prospectus Supplement, the Registration Statement, copies of the documents incorporated by
        reference therein and any other materials permitted by the Securities Act<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">.</font></font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>SECTION 2</u></font>. &#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>REPRESENTATIONS OF THE PLACEMENT AGENT</u></font>. The Placement Agent&#160; represents and warrants that it (i) is a member in good standing of FINRA, (ii) is registered as a broker/dealer under
      the Exchange Act, (iii) is licensed as a broker/dealer under the laws of the states applicable to the offers and sales of the Shares by such Placement Agent, (iv) is and will be a body corporate validly existing under the laws of its place of
      incorporation, (v) has full power and authority to enter into and perform its obligations under this Agreement<font style="font-size: 8pt; font-family: 'Times New Roman', Times, serif;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">and (vi) has not disclosed to any Purchaser information that is different from or inconsistent with the information contained in the</font> Base Prospectus, the Time of Sale Prospectus, the Prospectus Supplement<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and the Transaction Documents.</font>.&#160; The Placement Agent will immediately notify the Company in writing of any change in its status as such. The Placement Agent covenants
      that it will use its reasonable best efforts to conduct the Placement hereunder in compliance with the provisions of this Agreement and the requirements of applicable law.&#160;&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>SECTION 3</u></font>. &#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>COMPENSATION</u></font>.&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In consideration of the services to be provided for hereunder, the Company shall pay to
        the Placement Agent or their respective designees their pro rata portion (based on the </font>Shares<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> placed) of the following compensation with respect to the </font>Shares<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> which they are placing:</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">A.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">A cash fee (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Cash Fee</font>&#8221;) equal<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"> to an aggregate of six percent (6.0%) of the aggregate gross proceeds raised in the Placement.&#160; The Cash Fee shall be paid at the closing of the Placement (the &#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Closing</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221;).</font></font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">B.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Subject to compliance with FINRA Rule 5110(g)(5), the Company also agrees, in case of Closing of the Placement, to reimburse the Placement Agent for
        all travel and other out-of-pocket expenses incurred, including the reasonable fees, costs and disbursements of its legal counsel, in an amount not to exceed an aggregate of $60,000. The Company will reimburse Placement Agent directly upon the
        Closing of the Placement from the gross proceeds raised in the Placement.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">C.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">The Placement Agent reserves the right to reduce any item of its compensation or adjust the terms thereof as specified herein in the event that a
        determination shall be made by FINRA to the effect that such Placement Agent&#8217;s aggregate compensation is in excess of FINRA rules or that the terms thereof require adjustment.</font></div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>SECTION 4</u></font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>INDEMNIFICATION</u></font>. The Company agrees to the indemnification and other agreements set forth in the Indemnification Provisions (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Indemnification</font>&#8221;) attached as <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Exhibit A</u></font> to the Engagement
      Agreement, dated June 27, 2023, by and between the Company and the Placement Agent, the provisions of which are incorporated herein by reference and shall survive the termination or expiration of this Agreement.</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>SECTION 5</u></font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>ENGAGEMENT TERM</u></font>. The Placement Agent&#8217;s engagement hereunder shall be until the earlier of (i) the final closing date of the Placement and (ii) the date a party terminates the
      engagement by providing ten (10) days&#8217; written notice to the other party (the period of time during which this Agreement remains in effect is referred to herein as the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Term</font>&#8221;).&#160; Notwithstanding anything to the contrary contained herein, the provisions concerning confidentiality and indemnification and contribution contained herein and the Company&#8217;s obligations contained in the
      Indemnification Provisions will survive any expiration or termination of this Agreement. The Placement Agent agrees not to use any confidential information concerning the Company provided to the Placement Agent by the Company for any purposes other
      than those contemplated under this Agreement.</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </font><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>SECTION 6</u></font>.&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>PLACEMENT AGENT INFORMATION</u></font>. The Company agrees that any information or advice rendered by the Placement Agent in connection with this engagement is for the confidential use of the
      Company only in their evaluation of the Placement and, except as otherwise required by law, the Company will not disclose or otherwise refer to the advice or information in any manner without the Placement Agent&#8217;s prior written consent.</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>SECTION 7</u></font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>NO FIDUCIARY RELATIONSHIP</u></font>. This Agreement does not create, and shall not be construed as creating rights enforceable by any person or entity not a party hereto, except those
      entitled hereto by virtue of the Indemnification Provisions hereof. The Company acknowledges and agrees that the Placement Agent is not and shall not be construed as a fiduciary of the Company and shall have no duties or liabilities to the equity
      holders or the creditors of the Company or any other person by virtue of this Agreement or the retention of such Placement Agent hereunder, all of which are hereby expressly waived.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>SECTION 8</u></font>.&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>CLOSING</u></font>. The obligations of the Placement Agent, and the closing of the sale of the Shares hereunder are subject to the accuracy, when made and on the Closing Date, of the
      representations and warranties on the part of the Company and its subsidiaries contained herein and in the Purchase Agreement, to the accuracy of the statements of the Company and its subsidiaries made in any certificates pursuant to the provisions
      hereof, to the performance by the Company and its subsidiaries of their obligations hereunder, and to each of the following additional terms and conditions, except as otherwise disclosed to and acknowledged and waived by the Placement Agent to the
      Company:</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">A.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">No stop order suspending the effectiveness of the Registration Statement shall have been issued and no proceedings for that purpose shall have been
        initiated or threatened by the Commission, and any request for additional information on the part of the Commission (to be included in the Registration Statement, the Base Prospectus, the Prospectus Supplement or otherwise) shall have been complied
        with to the reasonable satisfaction of the Placement Agent. Any filings required to be made by the Company in connection with the Placement shall have been timely filed with the Commission.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">B.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">The Placement Agent shall not have discovered and disclosed to the Company on or prior to the Closing Date that the Registration Statement, the Base
        Prospectus, the Prospectus Supplement or any amendment or supplement thereto contains an untrue statement of a fact which, in the reasonable opinion of counsel for the Placement Agent, is material or omits to state any fact which, in the reasonable
        opinion of such counsel, is material and is required to be stated therein or is necessary to make the statements therein not misleading.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">C.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">All corporate proceedings and other legal matters incident to the authorization, form, execution, delivery and validity of each of this Agreement,
        the Shares, the Registration Statement, the Base Prospectus and the Prospectus Supplement and all other legal matters relating to this Agreement and the transactions contemplated hereby shall be reasonably satisfactory in all material respects to
        counsel for the Placement Agent, and the Company shall have furnished to such counsel all documents and information that they may reasonably request to enable them to pass upon such matters.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">D.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">The Placement Agent shall have received from outside counsel to the Company such counsel&#8217;s written opinions, addressed to the Placement Agent and
        the Purchasers and dated as of the Closing Date, in form and substance reasonably satisfactory to the Placement Agent and Placement Agent&#8217;s legal counsel.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">E.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">On the Closing Date, the Placement Agent shall have received a &#8220;comfort&#8221; letter from <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Marcum LLP (the Company&#8217;s current independent registered accounting firm) (&#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Marcum</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221;) and from Friedman LLP (the Company&#8217;s previous independent registered accounting
          firm) (&#8220;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Friedman</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#8221;) </font>as of each such
        date, addressed to each of the Placement Agent and in form and substance satisfactory in all respects to the Placement Agent and Placement Agent&#8217;s counsel.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">F.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">On the Closing Date, Placement Agent shall have received a certificate of the chief executive officer of the Company, dated, as applicable, as of
        the date of such Closing, to the effect that, as of the date of this Agreement and as of the applicable date, the representations and warranties of the Company contained herein and in the Purchase Agreement were and are accurate in all material
        respects, except for such changes as are contemplated by this Agreement and except as to representations and warranties that were expressly limited to a state of facts existing at a time prior to the applicable Closing Date, and that, as of the
        applicable date, the obligations to be performed by the Company hereunder on or prior thereto have been fully performed in all material respects.&#160; If necessary, on the Closing Date, the Placement Agent shall have received a certificate of the chief
        financial officer of the Company, dated as of the Closing Date, providing a customary certification as to such accounting or financial matters that are included or incorporated by reference in the Registration Statement or the Prospectus Supplement
        that <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Marcum or Friedman are unable to provide assurances on in the letter contemplated by Section 8(E) above.</font></font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">G.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">On the Closing Date, Placement Agent shall have received a certificate of the Secretary of the Company, dated, as applicable, as of the date of such
        Closing, certifying to the organizational documents, good standing in the state of incorporation of the Company and board resolutions relating to the Placement of the Shares from the Company.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">H.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Neither the Company nor any of its subsidiaries (i) shall have sustained since the date of the latest audited financial statements included or
        incorporated by reference in the Registration Statement, the Base Prospectus and the Prospectus Supplement, any loss or interference with its business from fire, explosion, flood, terrorist act or other calamity, whether or not covered by
        insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as set forth in or contemplated by the Registration Statement, the Base Prospectus and the Prospectus Supplement, (ii) since such date there shall
        not have been any change in the capital stock or long-term debt of the Company or any of its subsidiaries or any change, or any development involving a prospective change, in or affecting the business, general affairs, management, financial
        position, stockholders' equity, results of operations or prospects of the Company and its subsidiaries, otherwise than as set forth in or contemplated by the Registration Statement, the Base Prospectus and the Prospectus Supplement, and (iii) since
        such date there shall not have been any new or renewed inquiries by the Commission, FINRA or any other regulatory body regarding the Company, the effect of which, in any such case described in clause (i), (ii) or (iii), is so material and adverse
        as to make it impracticable or inadvisable to proceed with the sale or delivery of the Shares on the terms and in the manner contemplated by the Base Prospectus, Time of Sale Prospectus and Prospectus Supplement.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">I.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">The Common Stock is registered under the Exchange Act and, as of the Closing Date, the Company shall have applied to list the Shares on the Trading
        Market or other applicable U.S. national exchange and satisfactory evidence of such action shall have been provided to the Placement Agent. The Company shall have taken no action designed to, or likely to have the effect of terminating the
        registration of the Common Stock under the Exchange Act or delisting or suspending from trading the Common Stock from the Trading Market or other applicable U.S. national exchange, nor has the Company received any information suggesting that the
        Commission or the Trading Market or other U.S. applicable national exchange is contemplating terminating such registration or listing.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">J.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any governmental agency or
        body which would, as of the Closing Date, prevent the issuance or sale of the Shares or materially and adversely affect or potentially and adversely affect the business or operations of the Company; and no injunction, restraining order or order of
        any other nature by any federal or state court of competent jurisdiction shall have been issued as of the Closing Date which would prevent the issuance or sale of the Shares or materially and adversely affect or potentially and adversely affect the
        business or operations of the Company.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">K.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">The Company shall have prepared and filed with the Commission a Current Report on Form 8-K with respect to the Placement, including as an exhibit
        thereto this Agreement.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">L.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">The Company shall have entered into a Purchase Agreement with each of the Purchasers and such agreements shall be in full force and effect and shall
        contain representations, warranties and covenants of the Company as agreed between the Company and the Purchasers.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">M.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">FINRA shall have raised no objection to the fairness and reasonableness of the terms and arrangements of this Agreement. In addition, the Company
        shall, if requested by the Placement Agent, make or authorize Placement Agent&#8217;s counsel to make on the Company&#8217;s behalf, any filing with the FINRA Corporate Financing Department pursuant to FINRA Rule 5110 with respect to the Placement and pay all
        filing fees required in connection therewith.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 72pt; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">N.</font><font class="TRGRRTFtoHTMLTab" style="display: inline-block; text-indent: 0px; font-size: 1px; width: 36pt;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">Prior to the Closing Date, the Company shall have furnished to the Placement Agent such further information, certificates and documents as the
        Placement Agent may reasonably request.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If any of the conditions specified in this Section 8 shall not have been fulfilled when and as required by this Agreement, or if any of
      the certificates, opinions, written statements or letters furnished to the Placement Agent or to Placement Agent&#8217;s counsel pursuant to this Section 8 shall not be reasonably satisfactory in form and substance to the Placement Agent and to Placement
      Agent&#8217;s counsel, all obligations of the Placement Agent hereunder may be cancelled by the Placement Agent at, or at any time prior to, the consummation of the Closing. Notice of such cancellation shall be given to the Company in writing or orally.
      Any such oral notice shall be confirmed promptly thereafter in writing.</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>SECTION 9</u>.</font><font style="width: 9pt; font-size: 1px; display: inline-block;" class="HorizontalTab"> &#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>[RESERVED]</u>.</font></font></div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>SECTION 10</u></font>.&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>GOVERNING LAW</u></font>. This Agreement will be governed by, and construed in accordance with, the laws of the State of New York applicable to agreements made and to be performed entirely in such
      State, without regard to the conflicts of laws principles thereof. This Agreement may not be assigned by either party without the prior written consent of the other party. This Agreement shall be binding upon and inure to the benefit of the parties
      hereto, and their respective successors and permitted assigns. Any right to trial by jury with respect to any dispute arising under this Agreement or any transaction or conduct in connection herewith is waived. Any dispute arising under this
      Agreement may be brought into the courts of the State of New York or into the federal court located in New York, New York and, by execution and delivery of this Agreement, the Company hereby accepts for itself and in respect of its property,
      generally and unconditionally, the jurisdiction of aforesaid courts. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by delivering a copy thereof via
      overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
      herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. The Company agrees that a final judgment in any such action, proceeding or counterclaim brought in any such court shall be conclusive and binding
      upon the Company and may be enforced in any other courts to the jurisdiction of which the Company is or may be subject, by suit upon such judgment.&#160; If either party shall commence an action or proceeding to enforce any provisions of a Transaction
      Document, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorney's fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.&#160;
      This paragraph shall survive any termination of this Agreement, in whole or in part.</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>SECTION 11</u></font>.&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>ENTIRE AGREEMENT/MISC</u></font>. This Agreement (including the attached Indemnification Provisions) embodies the entire agreement and understanding between the parties hereto, and supersedes all
      prior agreements and understandings, relating to the subject matter hereof. Notwithstanding anything herein to the contrary, the Engagement Agreement shall continue to be effective and the terms therein shall continue to survive and be enforceable by
      the Placement Agent in accordance with its terms, provided that, in the event of a conflict between the terms of the Engagement Agreement and this Agreement, the terms of this Agreement shall prevail.<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</font>If any provision of this Agreement is determined to be invalid or unenforceable in any respect, such determination will not affect such provision in any other respect or any other provision of this Agreement,
      which will remain in full force and effect. This Agreement may not be amended or otherwise modified or waived except by an instrument in writing signed by both Placement Agent and the Company. The representations, warranties, agreements and covenants
      contained herein shall survive the closing of the Placement and delivery of the Shares. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become
      effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or a .pdf
      format file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or .pdf signature page were an original thereof.</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 27.35pt; margin-bottom: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>SECTION 12</u>.<font style="width: 9pt; font-size: 1px; display: inline-block;" class="HorizontalTab"> &#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>CONFIDENTIALITY</u></font>.&#160; The Placement Agent (i) will keep the Confidential Information (as such term is defined
        below) confidential and will not (except as required by applicable law or stock exchange requirement, regulation or legal process (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Legal Requirement</font>&#8221;),
        without the Company&#8217;s prior written consent, disclose to any person any Confidential Information, and (ii) will not use any Confidential Information other than in connection with the Placement.&#160; The Placement Agent further agrees to disclose the
        Confidential Information only to its Representatives (as such term is defined below) who need to know the Confidential Information for the purpose of the Placement, and who are informed by the Placement Agent of the confidential nature of the
        Confidential Information. The term &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Confidential Information</font>&#8221; shall mean, all confidential, proprietary and non-public information (whether
        written, oral or electronic communications) furnished by the Company to the Placement Agent or its Representatives in connection with the Placement Agent&#8217;s evaluation of the Placement. The term &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Confidential Information</font>&#8221; will not, however, include information which (i) is or becomes publicly available other than as a result of a disclosure by the Placement Agent or its Representatives in
        violation of this Agreement, (ii) is or becomes available to the Placement Agent or any of its Representatives on a non-confidential basis from a third-party, (iii) is known to the Placement Agent or any of its Representatives prior to disclosure
        by the Company or any of its Representatives, or (iv) is or has been independently developed by the Placement Agent and/or the Representatives without use of any Confidential Information furnished to it by the Company. The term &#8220;Representatives&#8221;
        shall mean the Placement Agent&#8217;s directors, board committees, officers, employees, financial advisors, attorneys and accountants. This provision shall be in full force until the earlier of (a) the date that the Confidential Information ceases to be
        confidential and (b) five years from the date hereof.&#160; Notwithstanding any of the foregoing, in the event that the Placement Agent or any of its Representatives are required by Legal Requirement to disclose any of the Confidential Information, the
        Placement Agent and its Representatives will furnish only that portion of the Confidential Information which the Placement Agent or its Representative, as applicable, is required to disclose by Legal Requirement as advised by counsel, and will use
        reasonable efforts to obtain reliable assurance that confidential treatment will be accorded the Confidential Information so disclosed.</font></div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>SECTION 13</u></font>.<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>NOTICES</u></font>. Any and all notices or other communications or deliveries required or
      permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is sent to the email address specified on the signature pages attached
      hereto prior to 6:30 p.m. (New York City time) on a business day, (b) the next business day after the date of transmission, if such notice or communication is sent to the email address on the signature pages attached hereto on a day that is not a
      business day or later than 6:30 p.m. (New York City time) on any business day, (c) the third business day following the date of mailing, if sent by U.S. internationally recognized air courier service, or (d) upon actual receipt by the party to whom
      such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages hereto.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>SECTION 14</u>.</font><font style="width: 9pt; font-size: 1px; display: inline-block;" class="HorizontalTab"> &#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>PRESS ANNOUNCEMENTS</u></font>. The Company agrees that the Placement Agent shall, from and after any Closing, have the right to reference the Placement
        and the Placement Agent&#8217;s role in connection therewith in the Placement Agent&#8217;s marketing materials and on its website and to place advertisements in financial and other newspapers and journals, in each case at its own expense.</font></div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Please confirm that the foregoing correctly sets forth our agreement by signing and returning to the Placement Agent the enclosed copy
      of this Agreement.</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z120886fcb6a9465db99d88a755b40e7c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 47.35%; vertical-align: top;">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 52.65%; vertical-align: top;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.35%; vertical-align: top;">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 52.65%; vertical-align: top;" colspan="2">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.35%; vertical-align: top;">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 52.65%; vertical-align: top;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">TITAN PARTNERS GROUP LLC, A DIVISION OF AMERICAN CAPITAL PARTNERS, LLC</div>
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.35%; vertical-align: top;">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 52.65%; vertical-align: top;" colspan="2">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.35%; vertical-align: top;">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 8.29%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:&#160;</div>
          </td>
          <td style="width: 44.36%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 47.35%; vertical-align: top;">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 8.29%; vertical-align: top;">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 44.36%; vertical-align: top;">
            <div style="text-align: left; text-indent: 6.15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.35%; vertical-align: top;">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 8.29%; vertical-align: top;">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 44.36%; vertical-align: top;">
            <div style="text-align: left; text-indent: 6.15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title:</div>
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.35%; vertical-align: top;">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 52.65%; vertical-align: top;" colspan="2">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.35%; vertical-align: top;">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 52.65%; vertical-align: top;" colspan="2">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><u>Address for notice</u>:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.35%; vertical-align: top;">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 52.65%; vertical-align: top;" colspan="2">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">[_____]</div>
          </td>
        </tr>
        <tr>
          <td style="width: 47.35%; vertical-align: top;">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 52.65%; vertical-align: top;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 47.35%; vertical-align: top;">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 52.65%; vertical-align: top;" colspan="2">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Attention:</div>
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Email:</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accepted and Agreed to as of</div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the date first written above:</div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z31483da7885446beaebb74e0dd9749ad" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 100%; vertical-align: top;" colspan="4">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">BIORESTORATIVE THERAPIES, INC.</div>
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 97.44%; vertical-align: middle;" colspan="3">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 2.56%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8.28%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:&#160;</div>
          </td>
          <td style="width: 38.07%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 53.65%; vertical-align: top;" colspan="2">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.28%; vertical-align: top;">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 38.07%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name: Lance Alstodt</div>
          </td>
          <td style="width: 53.65%; vertical-align: top;" colspan="2">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.28%; vertical-align: top;">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 38.07%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title:&#160; Chief Executive Officer</div>
          </td>
          <td style="width: 53.65%; vertical-align: top;" colspan="2">
            <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Address for notice</u></font>:</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">BioRestorative Therapies, Inc.</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">40 Marcus Drive, Suite One</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Melville, New York 11747</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Attention: </font>Lance Alstodt, CEO</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Email: <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">lalstodt@biorestorative.com</font></div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">[<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Signature Page to [___], 2023 Placement Agency Agreement</font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Between</font></div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Titan Partners Group LLC, a division of American Capital Partners, LLC</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">and BioRestorative Therapies, Inc.</font>]</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ex99_1.htm
<DESCRIPTION>PRESS RELEASE DATED JULY 11, 2023
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Certilman Balin Adler & Hyman, LLP
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>Exhibit 99.1<br>
    <div><br>
    </div>
    <div>
      <div><br>
      </div>
      <div style="text-align: center; margin-top: 12pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">BioRestorative Therapies Announces $2.1 Million Registered Direct Offering</div>
      <div><br>
      </div>
    </div>
    <div>
      <div style="text-align: justify; margin-bottom: 15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">MELVILLE, N.Y., July 11, 2023 (GLOBE
          NEWSWIRE) --&#160;</font>BioRestorative Therapies, Inc. (&#8220;BioRestorative&#8221;, &#8220;BRTX&#8221; or the &#8220;Company&#8221;) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into a definitive agreement with several
        accredited and institutional investors for the sale of 685,033 shares of the Company&#8217;s common stock at an offering price of $3.03 per share in a registered direct offering. The gross proceeds of the offering will be approximately $2.1 million,
        before deducting placement agent fees and other estimated offering expenses. The closing of the offering is expected to take place on or about July 13, 2023, subject to the satisfaction of customary closing conditions.</div>
      <div style="text-align: justify; margin-bottom: 15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company intends to use the net proceeds of the offering in connection with its clinical trials with respect to its lead cell
        therapy candidate,&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">BRTX-100&#160;</font>, pre-clinical research and development with respect to its metabolic&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">ThermoStem Program&#160;</font>and for general corporate purposes and working capital.</div>
      <div style="text-align: justify; margin-bottom: 15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Titan Partners Group, a division of American Capital Partners, LLC, is acting as sole placement agent for the offering.</div>
      <div style="text-align: justify; margin-bottom: 15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The shares in the offering are being offered by the Company pursuant to a shelf registration statement on Form S-3 (File No.
        333-269631) previously filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) and declared effective by the SEC on February 14, 2023. The offering is being made only by means of a prospectus, including a prospectus supplement, forming a
        part of the effective registration statement, relating to the offering, which will be filed with the SEC and will be available on the SEC&#8217;s website located at&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">http://www.sec.gov&#160;</font>.
        Electronic copies of the final prospectus supplement and accompanying prospectus may also be obtained, when available, from Titan Partners Group, a division of American Capital Partners, LLC, 7 World Trade Center, 46&#160;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th&#160;</sup>Floor, New York,
        NY 10007, Telephone: (929) 833-1246; Email:&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">info@titanpartnersgrp.com&#160;</font>.</div>
      <div style="text-align: justify; margin-bottom: 15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be
        any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</div>
      <div style="text-align: justify; margin-bottom: 15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About BioRestorative Therapies, Inc.</div>
      <div style="text-align: justify; margin-bottom: 15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">BioRestorative Therapies, Inc. (&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">www.biorestorative.com&#160;</font>)
        develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:</div>
      <div style="text-align: justify; margin-bottom: 15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226; Disc/Spine Program (brtxDISC&#160;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8482;&#160;</sup>): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous
        (or a person&#8217;s own) cultured mesenchymal stem cells collected from the patient&#8217;s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a
        surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient&#8217;s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure,
        BRTX-100 is to be injected by a physician into the patient&#8217;s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a
        Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We are also investigating the expansion of the clinical application of BRTX-100 to other indications within the body.</div>
      <div style="text-align: justify; margin-bottom: 15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226; Metabolic Program (ThermoStem&#160;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;&#160;</sup>): We are developing a cell-based therapy candidate to target obesity and metabolic
        disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (&#8220;BAT&#8221;). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates
        that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and
        diabetes.</div>
      <div style="text-align: justify; margin-bottom: 15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Forward-Looking Statements</div>
      <div style="text-align: justify; margin-bottom: 15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act
        of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.&#160;The words
        &#8220;believe,&#8221; &#8220;look forward to,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;is likely,&#8221; &#8220;will,&#8221; &#8220;expect&#8221; and similar expressions, as they relate to us, are intended to identify
        forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding the anticipated closing of the offering and the intended use of proceeds. You are cautioned that such statements are
        subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including,
        without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on
        such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.</div>
      <div><br>
      </div>
    </div>
    <div>
      <div style="text-align: left; margin-bottom: 15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Investor Contact:</div>
      <div style="text-align: left; margin-bottom: 15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Email:&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">ir@biorestorative.com</font></div>
      <div><br>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>brtx-20230711.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<xs:schema targetNamespace="http://biorestorative.com/20230711" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:brtx="http://biorestorative.com/20230711" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20230711_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="brtx-20230711_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://biorestorative.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>brtx-20230711_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>brtx-20230711_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://biorestorative.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="brtx-20230711.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !) I\# 2(  A$! Q$!_\0
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M16O@CPY:20-;:5!'Y$@EB4%MJ,#D$+G'!HYZ?)R*^_Z>H<E3GYW;;]?0Y?\
MLRTU3XT:S'>+(VS28"ICF>,C+L#RI%3^![Z3POKDO@O69,C+3Z3=/Q]IB))*
M$]Y%).>YZUUZ>'M*CUE]62S1=2D&'N QW,/0\]/;I4NLZ+INM111ZK9PW2Q/
MYD?F+RC>JGJ#]*;KQDN5[67R:ZH2H2B^9;W?W/HSB]4&_P"-=O&.K^'I%_\
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M&U:/RC%CY2F,;<>F.*KZQMIJG^%[V^\GZOOKT_&UK_<>>75POB'PMX*T5)&
MU:.&>X*-AA!$BN_/;+;%_&L[XI:-_P (\^C^)H+J]G%G<"WNC<3F3$$G!Z]
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M..C#T-6*BK552SMKU+I4G3NKZ= HHHK$V"BBB@ HHHH **** "BBB@ HHHH
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M-10!#]H'_/.;_OV:/M _YYS?]^S4U% $/V@?\\YO^_9H^T#_ )YS?]^S4U%
M$/V@?\\YO^_9H^T#_GG-_P!^S4U% $/V@?\ /.;_ +]FC[0/^><W_?LU-10!
M#]H'_/.;_OV:/M _YYS?]^S4U% $/V@?\\YO^_9H^T#_ )YS?]^S4U% $/V@
M?\\YO^_9H^T#_GG-_P!^S4U% $/V@?\ /.;_ +]FC[0/^><W_?LU-10!#]H'
M_/.;_OV:/M _YYS?]^S4U% $/V@?\\YO^_9H^T#_ )YS?]^S4U% $/V@?\\Y
MO^_9H^T#_GG-_P!^S4U% $/V@?\ /.;_ +]FC[0/^><W_?LU-10!#]H'_/.;
M_OV:/M _YYS?]^S4U% $/V@?\\YO^_9H^T#_ )YS?]^S4U% $/V@?\\YO^_9
MH^T#_GG-_P!^S4U% $/V@?\ /.;_ +]FC[0/^><W_?LU-10!#]H'_/.;_OV:
M/M _YYS?]^S4U% $/V@?\\YO^_9H^T#_ )YS?]^S4U% $/V@?\\YO^_9H^T#
M_GG-_P!^S4U% $/V@?\ /.;_ +]FC[0/^><W_?LU-10!#]H'_/.;_OV:/M _
MYYS?]^S4U% $/V@?\\YO^_9H^T#_ )YS?]^S4U% $/V@?\\YO^_9H^T#_GG-
M_P!^S4U% $/V@?\ /.;_ +]FC[0/^><W_?LU-10!#]H'_/.;_OV:/M _YYS?
M]^S4U% $/V@?\\YO^_9H^T#_ )YS?]^S4U% $/V@?\\YO^_9H^T#_GG-_P!^
MS4U% $/V@?\ /.;_ +]FC[0/^><W_?LU-10!#]H'_/.;_OV:/M _YYS?]^S4
MU% $/V@?\\YO^_9H^T#_ )YS?]^S4U% $/V@?\\YO^_9H^T#_GG-_P!^S4U%
; $/V@?\ /.;_ +]FI(Y!("0K#_>7%.HH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139920838779312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 11, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 11,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioRestorative Therapies, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001505497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">30-1341024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">40 Marcus Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Melville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">760-8100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BRTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>form8kdtd07112023_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="brtx-20230711.xsd" xlink:type="simple"/>
    <context id="c20230711to20230711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2023-07-11</startDate>
            <endDate>2023-07-11</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20230711to20230711"
      id="Fact_57ceb1ef023543318985e8bd0e45e890">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20230711to20230711"
      id="Fact_7373dd1aa23f4895bcc44a2d4b5a7646">0001505497</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20230711to20230711"
      id="Fact_c84329cecbed42efb8c9ec7782a0dc7f">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20230711to20230711"
      id="Fact_51a9baca9f4646ce91064466f3412b3a">2023-07-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20230711to20230711"
      id="Fact_0f5eaf8704c542c9bc0c5ee2fe6d3136">BioRestorative Therapies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20230711to20230711"
      id="Fact_8ae875c516fd4621ac0308557708d402">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20230711to20230711"
      id="Fact_68d36ba51bee4918a7ffb96c8ba84153">001-37603</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20230711to20230711"
      id="Fact_6ddffba6f23b4162af2814a714ffda92">30-1341024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20230711to20230711"
      id="Fact_753b20eef43b436196eb0b8eab6deccd">40 Marcus Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20230711to20230711"
      id="Fact_0311f9a9dc204ecfa1381e7c7399be94">Melville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20230711to20230711"
      id="Fact_c2fedba71bcc4544ba9725a27d45ef2d">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20230711to20230711"
      id="Fact_484ea381ac4e43219dd9dc43322a84a0">11747</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20230711to20230711"
      id="Fact_2a075e71a9ae481281424db10e1288cd">631</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20230711to20230711"
      id="Fact_1c15988241e94cf7bfd5e7779a12fb38">760-8100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20230711to20230711"
      id="Fact_9082fe7351a74f7db86d6d7023a5433e">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20230711to20230711"
      id="Fact_865eb3856cab4952856a090937718d3b">BRTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20230711to20230711"
      id="Fact_1497fd799cc24bacb5c9156a735b7680">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="c20230711to20230711"
      id="Fact_68c17f4c53bf43c48804a0324f88ef67">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20230711to20230711"
      id="Fact_2161e2eb022a42b8967438cf1a1ef348">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20230711to20230711"
      id="Fact_250cb1127b4a4f62acf3c2b81dd53016">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20230711to20230711"
      id="Fact_00629eb185c84c28be5d243f0d26f90b">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20230711to20230711"
      id="Fact_217436b5f8a646589c8f7c3d310163d0">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ..5[%8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #CE>Q6<KW0)N\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M:L,P#(=?9?B>*''&"B;-I66G#08K;.QF;+4UC?]@:R1]^R5>FS*V!]C1TL^?
M/H%:%83R$5^B#QC)8+H;;>^24&'-CD1! "1U1"M3.27<U-S[:"5-SWB (-5)
M'A!X53V 19):DH096(2%R+I6*Z$B2O+Q@M=JP8?/V&>85H ]6G24H"YK8-T\
M,9S'OH4;8(811IN^"Z@78J[^B<T=8)?DF,R2&H:A')J<FW:HX?WYZ36O6QB7
M2#J%TZ]D!)T#KMEU\ENSV>X>6<<KWA35JJCYCG-QOQ)5\S&[_O"["5NOS=[\
M8^.K8-?"K[OHO@!02P,$%     @ XY7L5IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9
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M)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M" #CE>Q6EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
M4$L#!!0    ( ..5[%8<.&7J/P$  #P"   /    >&PO=V]R:V)O;VLN>&UL
MC5'+;L) #/R5U7Y $U"+5$2XE#Z0JA:5BON2=8C%/B*O RU?7R=15*1>>O)Z
M;(UG9A?G2,=]C$?UY5U(A:Z9FWF6I;(&;])-;"#(I(KD#4M+ARPU!,:F&H"]
MRZ9Y/LN\P:"7BY%K0]EU$QE*QA@$[( =PCG]SKM6G3#A'AWR=Z'[MP.M/ ;T
M> %;Z%RK5,?S2R2\Q,#&;4N*SA5Z,@QV0(SE'WC;B?PT^]0C;/8?1H04>I8+
M8864N-_H^8UH/($L#UW+\0D= ZT,PS/%ML%PZ&C$179EH\]AK$.(<_I/C+&J
ML(15+%L/@8<<"5PG,*0:FZ15,!X*/:XH$ZQZ#"PAJ748J&2W<RJGUW9PS2+W
M*D.:HPQH;0?AHUH+%0:P;W(@"2[)E1M27>EYIK=WDWM)J'7N0;#W\!J-'<V/
M'[?\ 5!+ P04    " #CE>Q6)!Z;HJT   #X 0  &@   'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,75@K+A %\R,2$L6N
M"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO *1;M(HNSN,P3VH7
MK.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*
M%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)
MKM\,<'AT_@%02P,$%     @ XY7L5F60>9(9 0  SP,  !,   !;0V]N=&5N
M=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2
MVS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\
MFK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G 8ED\C<+,:DH9
MHS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM
M0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-
M"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&
M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #CE>Q6!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( ..5[%9RO= F[P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( ..5[%:97)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MXY7L5KNGY"=0!   DQ   !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ..5[%:?H!OPL0(  .(,   -
M          "  90,  !X;"]S='EL97,N>&UL4$L! A0#%     @ XY7L5I>*
MNQS     $P(   L              ( !< \  %]R96QS+RYR96QS4$L! A0#
M%     @ XY7L5APX9>H_ 0  / (   \              ( !61   'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( ..5[%8D'INBK0   /@!   :
M      "  <41  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( ..5[%9ED'F2&0$  ,\#   3              "  :H2  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /03      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="form8kdtd07112023.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8kdtd07112023.htm">form8kdtd07112023.htm</File>
    <File>brtx-20230711.xsd</File>
    <File>brtx-20230711_lab.xml</File>
    <File>brtx-20230711_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8kdtd07112023.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8kdtd07112023.htm"
     ]
    },
    "labelLink": {
     "local": [
      "brtx-20230711_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "brtx-20230711_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "brtx-20230711.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "brtx",
   "nsuri": "http://biorestorative.com/20230711",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form8kdtd07112023.htm",
      "contextRef": "c20230711to20230711",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://biorestorative.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form8kdtd07112023.htm",
      "contextRef": "c20230711to20230711",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001021771-23-000057-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001021771-23-000057-xbrl.zip
M4$L#!!0    ( ..5[%:K 7;)3 ,  $L/   1    8G)T>"TR,#(S,#<Q,2YX
M<V2U5]]OTS 0?D?B?S!YSZ]F@[5:-X&VH4F#H0$2;\AUKJU%8@?;6=/_'MN)
MV[1=2]/ F^W[[KOOSF?'N;RN\@P]@Y"4L[$7!Y&'@!&>4C8;>Z7TL224>M=7
MKU]=OO']C\! 8 4IFBS1!\%Q*F@Z _3EZ7%*,T"#)$B".#B/DXN6V?>->R5'
MDLPAQTAA,0/U&><@"TQ@[,V5*D9A.*%<@%1<1Z#/$!">AX-HD$3OXEBKRB '
MINZXR&]@BLM,C;W?)<[HE$+J(9T&DZ-*KL@6BT6P2 (N9IHDBL,?GQZ^VO .
M.Q&J.BYTC<\H^[7!7DU$YOB3T)@G6,)*R@Z^41,/A\/06E=0340/4%,F%68$
MVOA4K1S:X/.P-CJHWD&U+&!=EBF6$PMV%I/GP,&E4/OP*].&0PIT4X<$$LSX
M<Z@-FT EMI@W\M3FT)B-3^1'L3^(/=TT")FVP8QQI3>&,[O4+!8%95/>K.@U
M4]&1VX4GF");XY%A'7N2YD5F"FC7Y@*F8\\T@.]V^6<A(-!2'43P# YLB3&'
MVD7JEK3*'M:!'0469(=EIP<T"2] **H+NVZA\)^EE>%)U[2T"V3_-Q_#\TUG
M@,S@^]/]H7-H-=UP4IKC_YZEMTQ1M;S7>R]R6WH/T73L'42LPCL!*4PIH[:E
M(GT[1!'RD6-H#S%+44V'6GR7X3;)-G\I(7UD5W:\W2:-=P,YY$EP1LKL!,>U
MLOU^S:K;"G>TPJVS52]LGD!S_G3G<:$0V[G%VS?,#..BN0;JN_^!$TM3HZ6[
M-5[T"2%3TJV8CAX$E4Q=,QW4L.<J.JAA&VX&/:(27C(EEETBMUW<I(^"4@C]
M+>\FH>VSFO40 169=Q&PPMM1C\ ,4R*[1%X[U,,>L24E72([N!ETB[I]@P_K
MVY+!S#S27@Z_[98)L>'E&QX_'OCQV_XZ5&<-ZI3XF^54A>A4?H>WHWX;T'ZL
M'9.X=3$SW_F9]!.3?A*?K.(L%.:S?:0 BS9AS_SHPH^C;E7?>7@>&=4YF,#G
M1X?<]WSM\76Q-'V/7?,VTOJ(\J$J,LRP?L4L[_3\^"/09KE=DYQR(MKO]DXU
M<OBZ/N;5WZDT>_\73HW>=WM>^K/8*^9OGG8NUT+LXZ@FN_H#4$L#!!0    (
M ..5[%;NE$T9?@@  '18   5    8G)T>"TR,#(S,#<Q,5]L86(N>&ULS9QK
M;]LV%(:_#]A_X+PO&U#;M80-2]"XR+*D")8F09)B-PR%+-&.,%D,*+EQ_OU(
M76R1/*24BI+UI75XWO/R]AQ)5B*]>[]=1^@+IDE(XI/1;/)VA'#LDR",5R>C
M33+V$C\,1^_GWW[S[KOQ^ ..,?52'*#%"_J5$B^@8;#"Z/;N9AE&&#GNQ)W,
M)C_-W%\JX?&8IT=A_-\Q_V?A)1BQ;N/D>)N$)Z/'-'TZGDZ?GY\GS^Z$T-74
M>?MV-OWSX]6]_XC7WCB,D]2+?3Q"3'^<9(U7Q/?2;,R5].V"1J6!.]WUI57P
MG\:E;,R;QC-G[,XFVR08%4/DX0:=E/*MHB_F-#LZ.IIFT9V4&84&Z]VTV>HA
ME*\?)1&^PTO$__]T=ZG-/IIRQ33&Z96WP!'K,DM/7Y[PR2@)UT\1+ML>*5["
M/A&E.QN^.D=\=68_\]7Y?N\\;3.\%8?I@:1>9&><F9\Z5J6;]H.^MK6TIB%?
MVUQE5N2XAU6N=--^T+>8AB0XCX/N!RYW96OP]ZE'>T!%[:S]!+H?-3#4B#==
ML4]"OWB;XCC 0=DS]S8<.[.NLX-MYKSS)K[@&O&S"*'J=!+FFCDFV)^LR)=I
M@$/F[#C\PYA_R&;!?OA\1MCI\W21I-3ST](IF\3)"(RE8<K'+L6FXD!YOC!4
MBA.RH3Z6>E!&\#E:1*]:)&&/\Z'I3-<1ZY9?&.!X_.E^A,) IYUG3>B?LO'?
M=]/]J-69GE)Q7SSJET-B'VNF42BF/F$GRZ=T+,QH2<E:MP^D9OF*U<C\CI$@
M0RE!FMQIY\3]1OS-&L?I W.4<(!"Q33$4 O<JD:V: ,\=; ITGG9@GC384$#
MUY^8UTW$K*HJ*5,SNX?L#QJF[)![1M;K31SF%]N)1(-14TQ+HVG!'^AH"T23
MN8Y(?<Z\""$Q=EA&S;M&&BZR2"TH+_$U>'7/\3V)0C],V??9C^R"@X9>)"&E
M%Q13A 0M\%7M;+&K==:!JTF8[]M1&3@LLH8](DU65815U9:DZERZQ_268EX?
MF"U!=J3G%[OT9KG$5$*H7EA,UB1L@:_>UA;&M3WH<*Y)G+/XV*\(4*Y F>2P
M@#?85?*:]1>!U^>4X->Y]EX ETFRP;1Q&6CE<#$ <GLEH9AW5!BZ?AJ6!YRN
M%DFN&VZMZ+<>KACC]ACK1LG45(^FA^YKZ)3U'O 17$3>2@(5C!73E6(M2D%P
MLL4]9*J#7-7.=TV(MQV677@72,WBB50*LA)!(+>_&Q$78>)[T5_8HQ>L1?Z6
M6*.2;D\H*@MW*B1/VS<M8/NZ^Q=0UOY61AY%/(RR^##N:^CVD#1></ANAY0@
MW_@ _?KF.[_#7D\XH ,9%W36**^X=L.YVD$STN4\A?5<,#S:H?T$>=<LO8GX
M2@K,O.+9'_6[7XC]QKX+:X@'-1+MDL8"Z8*C;<HA\SK"U9P]W076+(AX=!AD
MP_M&&BXS3+0@EVD&O+HG^3QF(WVYPZN0_X(F3J^]M8R525),$Y:TP!@RM$6Q
MP5L'L39EGD?0/H1X[+ $&S>,-%M@D5](7>*K=^J+WC-6/-2++MF7R>WO^ 7$
M5Z,1^%4TK0&6'.T2#)N;$89R2H:+&,J"B$6'0+%NWTC#988XEN0BR*!77R1?
MA!&^WJP7RKT\75C@MQINC>[>S"ZUBJ\96$E>LLJ;4=X^!$J!C2'UBPFQN5>*
M6,H.?1'YX&TO U82X;+XK:0!SQJMP*I6VQI<C;-=BLV=F)$VY99\,PT210.B
MO6Z?R2NW ZH#39I8%$;OOBKD,O8)?2(T&\!]RJ[=S\B&G4->SD@ 7THWRA"J
MI2:C=<T8_>U63I.NS/53[U!6D:!\@S(M(A05>L03AE!0S8 @7[5C4'$9D\42
M:]!/7X5VOL9T%<:K#Y0\IX]G9/WDQ?#%OE$I%)9&V;J@0%^[A63JPEQ ^LRR
M<$H%RB6HT RA5LQ[2UZU"5!M@$EB31A\^ZJ%TR!@#";%?U=AC&=@)1AT0AV
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MPNV>L,#!.Z.IQ,/\8<FF77)L+^T\K"WA6&R0?T'?1>2+_,OVQ_\!4$L#!!0
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MI;(5C+7ZM*5.+"UXUF_*W6[TF"[)5SK7-5FWIE&[^>'K:'AFCG$S$VBJ7*%
MA5B*'>O< (=RKG2Y1?PK%4?N894R!S=RN>2VK1>N+FL">\%/<J$V2HF<EN;]
M(#N0$'6(KNMMK=?OZ>JA%/-[/UM5P2_KL")*1C&'> 8)7A"4&X92$@<+SF/=
MQ;F('Q+US!)UL6I$RT;VJ()4EN!7U2^XLQ+V8O(S2Q7@5P5)\ZH#677!F16
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M_A]02P$"% ,4    " #CE>Q6JP%VR4P#  !+#P  $0              @ $
M    8G)T>"TR,#(S,#<Q,2YX<V102P$"% ,4    " #CE>Q6[I1-&7X(  !T
M6   %0              @ %[ P  8G)T>"TR,#(S,#<Q,5]L86(N>&UL4$L!
M A0#%     @ XY7L5I?)_=SC!0  _3X  !4              ( !+ P  &)R
M='@M,C R,S W,3%?<')E+GAM;%!+ 0(4 Q0    ( ..5[%8<COE+"1<  +*
M   5              "  4(2  !F;W)M.&MD=&0P-S$Q,C R,RYH=&U02P4&
2      0 !  ( 0  ?BD

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
